VNRXGeneral
VolitionRx Announces Collaboration with Sysmex
VolitionRx Limited announced a collaboration with Sysmex to optimize its Nu.Q® NETs assay on Sysmex's platform. This partnership will focus on diseases associated with NETosis, which are critical for accurate diagnostics. The Nu.Q® NETs assay is expected to provide improved information for clinical decision-making and has a substantial market potential of $3.8 billion. VolitionRx aims to leverage Sysmex's expertise and resources to enhance the assay's capabilities for better patient outcomes.
Read more →VNRXGeneral
VolitionRx Announces Pricing of $4.6 Million Public Offering $4.6 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the full exercise of warrants
VolitionRx has priced a public offering of 2,960,000 shares at $1.55 per share, aiming to raise $4.6 million upfront. Additional proceeds of $2.3 million are possible from warrant exercises, but there is no guarantee that these warrants will be exercised. The offering is set to close on June 9, 2026, pending usual closing conditions. Maxim Group LLC is acting as the placement agent for this transaction.
Read more →VNRXGeneral
VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring
VolitionRx Limited has filed a new patent for its Nu.Q technology aimed at triaging and monitoring potential Ebola cases. This innovative approach focuses on the host's immune response instead of merely identifying the virus. The company is actively seeking strategic partners for trials and deployment in outbreak areas, emphasizing its potential impact in low-resource healthcare settings. The ongoing Ebola outbreaks underline the need for improved early detection methods, making Volition's advancements timely and critical.
Read more →VNRXGeneral
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
VolitionRx Limited reported significant commercial momentum with a 300% revenue growth in Q1 2026, reaching $1 million. The company's achievements include a clinical manuscript submission for a feline lymphoma test that could yield a $5 million milestone payment, and successful licensing discussions with major diagnostic firms. Additionally, advancements in cancer detection through the new Capture-Seq platform and ongoing projects in sepsis testing were highlighted, demonstrating the company's potential in high-value markets totaling over $27 billion.
Read more →VNRXConferences/Events
VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Friday, May 15 at 8:30 a.m. U.S. Eastern Time Henderson, Ne
VolitionRx Limited reported its financial results and business updates for the first quarter of 2026. The company achieved a revenue growth of approximately $1 million compared to the previous year, alongside promising advancements in its Nu.Q platform, including a feline lymphoma assay submission. However, the company's operating loss indicates ongoing financial pressures. Furthermore, reliance on partnerships and milestone payments presents uncertainties regarding future revenue generation.
Read more →VNRXConferences/Events
VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update
VolitionRx Limited has announced a conference call scheduled for May 15, 2026, to discuss its first quarter earnings and provide a business update. The call will feature key executives and will cover significant events from the first quarter, along with future milestones. A live audio webcast will also be available for participants.
Read more →VNRXGeneral
VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats
VolitionRx Limited has submitted a clinical manuscript for peer review regarding its Nu.Q® Vet Feline assay, which shows high accuracy in detecting lymphoma in cats. The assay demonstrated 97% specificity and detected 86% of feline lymphomas. This development could lead to the first affordable blood-based liquid biopsy test for feline cancer, addressing a significant need in veterinary medicine.
Read more →VNRXGeneral
Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing
VolitionRx Limited has achieved a significant technical milestone by successfully detecting nucleosomes in capillary blood from sepsis patients using a lateral flow prototype. This innovative finger-prick testing method can be applied in various settings, including emergency rooms and home testing, potentially transforming sepsis diagnostics. The company aims to address unmet diagnostic needs with a cost-effective solution, targeting expansion into low-income countries and enhancing patient outcomes through rapid decision-making capabilities.
Read more →VNRXGeneral
VolitionRx Announces Acceptance of Compliance Plan by NYSE American
VolitionRx Limited announced that its compliance plan was accepted by the NYSE American, allowing the company to retain its listing on the exchange. This decision is a response to a prior notification regarding non-compliance with listing standards due to insufficient stockholders' equity. The company has until August 6, 2027, to regain compliance, subject to periodic evaluation by the NYSE American. The company's listing remains unaffected during this compliance period, ensuring its ongoing business operations continue as normal.
Read more →VNRXGeneral
Volition Launches rNuQ™ Webshop Broadening Product Range
VolitionRx Limited has launched its rNuQ webshop, offering a range of recombinant nucleosomes for research. This initiative aims to enhance accessibility for researchers and is part of Volition's strategy to commercialize its products. The nucleosomes are manufactured under strict quality controls, and the company anticipates continued revenue growth in the coming year.
Read more →VNRXGeneral
VolitionRx krijgt 2,0 miljoen EUR aan niet-verwaterende financiering van regionale overheidsinstanties in BelgiëNederland - NederlandsUSA - EnglishFrance - Français
VolitionRx Limited has obtained an additional €2 million in non-dilutive funding from Namur Invest and Wallonie Entreprendre S.A. in Belgium. The funds will be used to advance their Nu.Q® product portfolio and regulatory transition program. This funding marks a significant milestone in Volition's financing strategy, bringing their total non-dilutive funding to over $25 million.
Read more →VNRXGeneral
VolitionRx obtient un financement non dilutif de 2 millions d'euros auprès d'organismes publics régionaux en BelgiqueFrance - FrançaisUSA - English
VolitionRx Limited has secured €2 million in non-dilutive funding from regional public organizations in Belgium. This funding will be utilized to advance the development of its Nu.Q® product portfolio, including regulatory transition and research for low-income countries. The company has expressed gratitude for the continued financial support, which is crucial for its operational strategy.
Read more →VNRXGeneral
VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium
VolitionRx Limited has secured €2.0 million in non-dilutive funding from Belgian government agencies to support the development of its Nu.Q® product portfolio. This funding will aid in regulatory transitions and the development of a Lateral Flow product for low-income countries. The total non-dilutive funding received by Volition now exceeds $25 million.
Read more →VNRXConferences/Events
VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Wednesday, April 1 at 8:30 a.m. U.S. Eastern Time Hender
VolitionRx Limited announced its financial results and business updates for the fiscal year 2025, highlighted by a 40% increase in revenue and a 133% growth in Q4. The company has begun clinical certification for its Nu.Q Cancer assays and is involved in a government-backed sepsis detection program worth approximately $7.3 million. Despite these successes, the company reported a net loss decrease of 14%, emphasizing ongoing financial challenges. A conference call is scheduled for April 1, 2026, to discuss these results and future milestones.
Read more →VNRXPhases
Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma Patients
VolitionRx Limited has published a clinical study in the Shock Journal revealing that its Nu.Q® biomarkers, specifically levels of H3.1 and H3R8 Citrulline, are significantly elevated in trauma patients. The study, conducted by a team at Mayo Clinic, analyzed 674 trauma cases, indicating that these levels are especially high among patients who develop complications such as Venous Thromboembolism. This research highlights the potential for Nu.Q® biomarkers to aid in early risk identification and guide treatment strategies in trauma care. The publication supports Volition’s ongoing efforts to commercialize their diagnostic products.
Read more →VNRXConferences/Events
Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference
VolitionRx Limited presented an abstract at the European Lung Cancer Conference, showcasing its Nu.Q® Cancer assays for managing lung cancer. The study revealed that measuring H3K27Me3-nucleosomes can help identify Non Small Cell Lung Cancer patients who may benefit from closer monitoring or secondary treatments. This advancement aims to enhance precision in treatment selection and improve patient outcomes.
Read more →VNRXConferences/Events
VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update
VolitionRx Limited has scheduled a conference call for April 1, 2026, to discuss its financial and operational results for the fiscal year 2025. The call will feature key executives, including the CEO and CFO, who will provide updates on significant events and future milestones. A live audio webcast will also be available for interested parties.
Read more →VNRXGeneral
Volition Announces Detection of Over 95% of Early-Stage Cancers
VolitionRx Limited has announced promising proof of concept data demonstrating its Capture-Seq™ technology's ability to detect over 95% of early-stage cancers. This breakthrough could revolutionize cancer diagnosis, offering a significant advancement in early detection methods. The announcement was made by Dr. Jake Micallef, the Chief Scientific Officer of Volition.
Read more →VNRXGeneral
Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA
VolitionRx Limited announced a breakthrough in liquid biopsy technology, achieving over 99% purity in isolating circulating tumor-derived DNA (ctDNA). This novel method, termed Capture-Seq™, shows promise for early detection of multiple cancers and the detection of minimal residual disease. Initial clinical validation results report no false positives and successful cancer detection in both early and later stages. The company is in discussions with diagnostic leaders to accelerate commercialization, targeting a significant total addressable market estimated at $36 billion.
Read more →VNRXGeneral
Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems
VolitionRx Limited (VNRX) has announced the successful validation of the automated version of its Nu.Q® Vet Cancer Test in collaboration with Fujifilm Vet Systems in Japan. This innovation will enhance the testing process by allowing full automation in laboratories, moving away from manual plates. The test has already generated significant interest among Japanese veterinarians, with over 1,700 veterinary hospitals registered to utilize the technology. The collaboration opens up substantial revenue opportunities, particularly in a market with approximately seven million pet dogs in Japan, where early cancer detection can lead to better health outcomes.
Read more →VNRXGeneral
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution
VolitionRx Limited has announced substantial clinical and commercial advancements, including the submission of a manuscript on a novel cancer detection method, Capture-Seq™. The company is preparing for a reimbursement submission for its Nu.Q® Cancer assays in lung cancer, aiming for routine clinical use by late 2026. Additionally, VolitionRx is involved in a government-funded study for early sepsis detection and has reported promising results for its veterinary cancer assays.
Read more →VNRXGeneral
Volition Announces the Appointment of New Distributor for Nu.Q® Discover
VolitionRx Limited has appointed Medical & Biological Laboratories Co. Ltd (MBL) as a non-exclusive distributor for its Nu.Q® Discover assays in Japan. This partnership aims to enhance the accessibility of Volition's nucleosome-based biomarkers for drug developers and researchers. The company anticipates significant revenue growth for Nu.Q® Discover in 2026, building on its success in 2025.
Read more →VNRXGeneral
VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
VolitionRx Limited received a notice from NYSE American regarding non-compliance with continued listing standards due to insufficient stockholders' equity. The company must submit a plan by March 8, 2026, to regain compliance by August 6, 2027. While shares will continue to trade, they will be marked as 'below compliance'.
Read more →VNRXGeneral
VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards HENDERSON, Nev., February, 9, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a mul
VolitionRx Limited has received a notice indicating non-compliance with NYSE American continued listing standards, primarily related to stockholders' equity. The company was informed that it does not meet the minimum equity requirements due to losses reported over recent fiscal years. VolitionRx must submit a plan by March 8, 2026, to address this and aims to regain compliance by August 6, 2027. Despite the notice, the company's shares will continue to trade, albeit with a designation indicating non-compliant status.
Read more →VNRXConferences/Events
Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation
VolitionRx Limited is sponsoring a symposium at the European Hidradenitis Suppurativa Foundation Conference in Malta, focusing on precision medicine using the Nu.Q®NETs assay. Professor Evangelos J. Giamarellos-Bourboulis will present findings from a clinical study demonstrating the assay's potential in managing Hidradenitis Suppurativa (HS). The study suggests that this blood test can help classify HS patients, guiding treatment decisions effectively.
Read more →VNRXFDA Updates
VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays
VolitionRx Limited is preparing a reimbursement submission for its Nu.Q® Cancer assays, supported by Hospices Civils de Lyon. The goal is to integrate the test into routine clinical practice for lung cancer management in France. This initiative is expected to enhance precision in treatment selection and monitoring, with hopes for implementation by late 2026.
Read more →VNRXGeneral
Volition Announces Data to Support Use of Nu.Q® NETs in New Indication
VolitionRx Limited has announced a new clinical study demonstrating the effectiveness of its Nu.Q® NETs assay in managing Hidradenitis Suppurativa (HS), a chronic disease affecting about 1% of the global population. The assay is CE-Marked and approved for clinical use in several European regions. The study highlights the potential for personalized treatment approaches and indicates a significant market opportunity for the assay.
Read more →VNRXGeneral
Volition Continues to Extend Access to Nu.Q® Vet Cancer Test
VolitionRx Limited has appointed two new centralized laboratory providers for its Nu.Q® Vet Cancer test, enhancing its availability in the U.S. and Asia. This initiative aims to facilitate earlier cancer detection in dogs, potentially impacting the $100 million canine screening market. The company emphasizes the importance of early detection in improving outcomes for pets.
Read more →VNRXConferences/Events
Volition Sponsors Symposium at Veterinary Meeting and Expo
VolitionRx Limited is sponsoring a symposium at the Veterinary Meeting and Expo in Orlando, Florida, where Dr. Sue Ettinger will present on the Nu.Q® Vet Cancer Test. This test aims to enhance early cancer detection in dogs during regular veterinary checkups. The event is expected to draw around 20,000 veterinary professionals, providing a platform to showcase Volition's innovative diagnostic solutions.
Read more →VNRXGeneral
VolitionRx Secures $2.0 Million in Funding HENDERSON, Nev., January, 8, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today t
VolitionRx Limited (NYSE AMERICAN: VNRX) announced an amended securities purchase agreement with Lind Global Asset Management, securing $2 million in funding. The deal includes a convertible promissory note and warrants for company shares. This funding will support Volition's ongoing development of innovative blood tests for early disease detection, particularly in cancer and related conditions. The company is required to meet certain conditions for the release of funds, creating some uncertainty going forward.
Read more →VNRXGeneral
VolitionRx Secures $2.0 Million in Funding
VolitionRx Limited has announced an amended securities purchase agreement, securing $2 million from Lind Global Asset Management. This agreement includes a senior secured convertible promissory note and a common stock purchase warrant, providing the company with financial backing to further its epigenetic research and development efforts. The funds are expected to assist in the commercialization of blood tests aimed at earlier disease detection and monitoring. VolitionRx remains committed to improving patient outcomes through innovative medical solutions.
Read more →VNRXPhases
VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats
VolitionRx Limited has announced promising clinical data from its Nu.Q® Vet Feline assay, showcasing its high accuracy in detecting lymphoma in cats. The test achieved 100% specificity, indicating no false positives, and effectively identified over 80% of feline lymphomas. This breakthrough positions the Nu.Q® Vet Feline Test as a potentially revolutionary, accessible liquid biopsy solution for feline cancer detection, catering to a vast market of pet cats. Volition anticipates this development will significantly increase its market presence and generate additional revenue through expanded product offerings in veterinary medicine.
Read more →VNRXGeneral
Volition Issues Business Review 2025
VolitionRx Limited reflects on its achievements in 2025, highlighting the receipt of its first order for Nu.Q® Cancer assays and the inclusion of its NETs assay in a significant government program in France. The company has made strides in commercializing its diagnostic platform and securing licensing agreements with major players in the industry. Volition aims to expand the use of its tests for early detection of cancer and sepsis, marking a transformative year for the company.
Read more →VNRXGeneral
Volition Solves Liquid Biopsy
VolitionRx Limited has developed a novel method known as Capture-Seq™ that significantly improves the detection of cancer biomarkers in blood samples. This advance allows for the isolation of ultrashort transcription factor-bound DNA while effectively removing background DNA, solving long-standing challenges in liquid biopsy technology. Initial studies demonstrate 100% sensitivity and specificity for early cancer detection, indicating high potential for commercialization. The company aims to partner with commercial entities to accelerate the launch of this promising technology.
Read more →VNRXConferences/Events
Volition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer
VolitionRx Limited presented two abstracts at the North America Conference on Lung Cancer, showcasing the Nu.Q® Cancer assays' effectiveness in managing lung cancer. The studies highlighted the assays' prognostic capabilities and their role in refining risk assessment for patients. The findings suggest that these tests could significantly enhance clinical decision-making and patient outcomes.
Read more →VNRXGeneral
VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of SepsisUSA - EnglishFrance - Français
VolitionRx Limited has announced the inclusion of its Nu.Q® NETs H3.1 assay in the DETECSEPS program, aimed at early detection of sepsis. The program, funded by the French government, seeks to improve emergency care pathways for at-risk patients. This collaboration with prominent hospitals and industry partners is expected to enhance diagnostic accuracy and reduce the burden of sepsis.
Read more →VNRXGeneral
VolitionRx Limited annonce l'intégration de son test Nu.Q® NETs en tant que biomarqueur innovant dans l'évaluation en vie réelle menée en France sur la détection précoce du sepsisFrance - FrançaisUSA - English
VolitionRx Limited has announced the integration of its Nu.Q® NETs test into the DETECSEPS project, aimed at early detection of sepsis. This initiative, backed by a €6.3 million funding from the French government, seeks to significantly reduce the socio-economic burden of sepsis. The project combines clinical scoring with the Nu.Q® H3.1 biomarker to enhance diagnostic accuracy in emergency settings.
Read more →VNRXGeneral
VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical UseUSA - EnglishUSA - EnglishFrance - Français
VolitionRx Limited has announced the first sale of its Nu.Q® Cancer assays to Hospices Civils de Lyon in France. This order is part of the internal certification process for routine clinical use in cancer management. The technology aims to enhance treatment decisions and improve patient outcomes in lung cancer management. This milestone represents a significant step in Volition's commercialization efforts.
Read more →VNRXGeneral
VolitionRx Limited annonce le premier contrat de vente des tests Nu.Q® Cancer pour la validation clinique en vue d'une utilisation pratique de soins courantsFrance - FrançaisUSA - English
VolitionRx Limited has announced its first sales contract for the Nu.Q® Cancer tests with Hospices Civils de Lyon in France. This partnership aims to validate the tests for clinical use in cancer management. The tests are designed to provide valuable prognostic information and improve treatment decisions for lung cancer patients. This milestone is seen as a significant advancement in Volition's mission to enhance cancer care.
Read more →VNRXGeneral
VolitionRx Limited Announces Third Quarter 2025 Financial Results and Business Update
VolitionRx Limited reported its financial results for Q3 2025, highlighting significant agreements with Werfen and Hologic. The company is actively pursuing additional partnerships with leading diagnostic firms and anticipates further licensing deals. Management expressed confidence in the potential of their Nu.Q® technology for cancer and sepsis detection, alongside plans for upcoming peer-reviewed publications.
Read more →VNRXConferences/Events
VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update
VolitionRx Limited has scheduled a conference call for November 14, 2025, to discuss its third quarter earnings and provide a business update. Key executives will present the financial results and highlight important events from the quarter. The call will also include a live audio webcast and a replay option available until November 28, 2025.
Read more →VNRXGeneral
Volition Donates Nu.Q® Vet Cancer Tests to HOPE Animal-Assisted Crisis Response Dogs
VolitionRx Limited has donated its Nu.Q® Vet Cancer Tests to the HOPE Animal-Assisted Crisis Response Dogs, enhancing support for therapy dogs that aid individuals in crisis. This initiative aligns with Volition's corporate social responsibility strategy and highlights their commitment to animal health. The donation was announced during the HOPE AACR Annual Conference in Virginia Beach.
Read more →VNRXGeneral
VolitionRx Limited Announces Pricing of $6.0 Million Underwritten Public Offering of Common Stock and Common Stock Warrants
VolitionRx Limited has announced the pricing of an underwritten public offering, aiming to raise approximately $6 million by selling 11.55 million shares of common stock and accompanying warrants. The offering is expected to close around October 14, 2025, and proceeds will be used for research, product development, and other corporate purposes. The company has granted the underwriter an option for additional shares to cover over-allotments.
Read more →VNRXGeneral
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock and Common Stock Warrants
VolitionRx Limited has proposed an underwritten public offering of its common stock and stock warrants. The company intends to use the proceeds for research, product development, clinical studies, and general corporate purposes, including potential acquisitions. Newbridge Securities Corporation serves as the sole book-running manager for this offering, which is contingent upon market conditions. The deadline for completion and the specifics of the offering remain uncertain, highlighting potential risks for investors.
Read more →VNRXConferences/Events
Volition Sponsors Upcoming GenomeWeb Webinar
VolitionRx Limited is sponsoring a GenomeWeb webinar focused on measuring epigenetic modifications for biomarker and drug discovery. Scheduled for October 8, the event will feature discussions led by Dr. Eric Ariazi on key epigenetic pathways and their implications in health and disease, as well as insights from Marielle Herzog regarding Volition's Nu.Q® assays. The company continues to emphasize its mission of advancing epigenetics while providing innovative tools aimed at improving disease diagnosis and monitoring.
Read more →VNRXGeneral
Volition Signs Co-Marketing and Services Agreement with Hologic
VolitionRx Limited has signed a co-marketing and services agreement with Hologic Diagenode to promote Volition's Nu.Q® Discover service. This collaboration is expected to enhance customer access to state-of-the-art assays for epigenetic profiling, thereby expanding their market reach. Hologic's extensive experience and substantial revenue from biotech and academic clients will likely contribute to the success of this partnership. If successful, Hologic may become the exclusive provider of these services, emphasizing the partnership's potential growth opportunities.
Read more →VNRXGeneral
Volition Signs First Human Out Licensing Deal
VolitionRx Limited has entered into a Research License and Exclusive Commercial Option Rights Agreement with Werfen for its Nu.Q® NETs test aimed at managing Antiphospholipid Syndrome (APS). This agreement reflects Volition's strategy to collaborate with global leaders in diagnostics to advance their proprietary technologies. Positive preliminary findings in NETs detection could lead to improvements in APS management and patient outcomes. The partnership could also allow Werfen to expand its testing portfolio in APS diagnostics.
Read more →VNRXConferences/Events
VolitionRx Limited Announces Second Quarter 2025 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Friday, August 15 at 8:30 a.m. U.S. Eastern Time Henderson
VolitionRx Limited announced its financial results for the second quarter of 2025, reporting a 15% revenue growth year-over-year. Net losses decreased significantly, indicating improved financial health. The company aims to finalize its first human diagnostics agreement this quarter as it continues discussions with multiple partners. A conference call is scheduled for August 15, 2025, to discuss these results and upcoming milestones.
Read more →VNRXConferences/Events
VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update
VolitionRx Limited has announced a conference call scheduled for August 15, 2025, at 8:30 a.m. U.S. Eastern Time. The call will discuss the company's financial and operational results for the second quarter of 2025, alongside important updates about their business. Senior executives will be present to provide insights into recent developments and future milestones, emphasizing the company’s commitment to advancements in epigenetics and disease detection.
Read more →VNRXGeneral
VolitionRx Announces Pricing of $1.2 Million Registered Direct Offering
VolitionRx Limited has announced a direct offering of $1.2 million, which includes the sale of 156,250 shares to insiders and 1,734,375 shares to other existing stockholders. The shares are priced at $0.64 each and come with warrants. The funds raised will support research, product development, and potential acquisitions. The offering is expected to close around August 5, 2025, pending customary closing conditions.
Read more →VNRXPhases
Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation
VolitionRx Limited (NYSE AMERICAN: VNRX) reported significant progress with its Nu.Q® Discover program, which focuses on epigenetic profiling and has captured a notable share of the market. The company anticipates continued growth in 2025, with multiple new contracts and strong demand for its assays as exploratory biomarkers in clinical trials. Nu.Q® Discover is currently serving over 20 clients globally and is expected to generate hundreds of thousands of dollars in revenue from major projects targeting cancer and other diseases. The success of the program enhances Volition's position in the competitive field of diagnostics and precision medicine.
Read more →VNRXGeneral
Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes
VolitionRx Limited has introduced a lateral flow test that quantifies nucleosomes in whole venous blood in minutes, demonstrating feasibility for rapid detection of immune disruptions in critical care settings. The study included 25 patients and indicated strong correlation with established laboratory assays. This advancement allows for quicker clinical decision-making and may enhance patient outcomes, particularly for conditions such as sepsis. Future phases aim to develop a finger-prick version of the test to further increase accessibility and ease of use.
Read more →VNRXPhases
Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure
VolitionRx Limited announced the publication of a peer-reviewed clinical study highlighting the Nu.Q® H3.1 biomarker's association with sepsis and organ failure in ICU patients. The study involved 1713 patients and suggests that H3.1 can play a significant role in patient stratification and monitoring. The findings indicate that higher concentrations of H3.1 correlates with acute conditions like kidney injury and respiratory distress, demonstrating its potential for clinical application. This research enhances the prospects for commercialization of Volition's diagnostic product in a growing market.
Read more →VNRXConferences/Events
Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties
VolitionRx Limited announced two oral presentations at the Asian Meeting of Animal Medicine Specialties, showcasing its Nu.Q® Vet Cancer Test. Dr. Masahiko Sato, a prominent veterinary expert, presented findings from clinical studies that demonstrate the test's potential in differentiating between various types of canine cancers. The event, held in Thailand, aims to raise awareness and adoption of this diagnostic tool among veterinary professionals in Asia. This initiative reflects Volition's commitment to advancing epigenetics in veterinary medicine.
Read more →VNRXPhases
VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats
VolitionRx Limited announced the publication of a study in BMC Veterinary Research that successfully detected nucleosomes in healthy cats. This advancement represents the first time such measurements have been reported for feline patients, which may facilitate cancer screening and monitoring in this species. The findings could lead to potential annual check-ups for a substantial portion of the U.S. cat population, estimated at over 60 million. VolitionRx aims to develop a product targeting feline lymphoma, the most common cancer in cats, thus expanding their diagnostic offerings beyond dogs and humans.
Read more →VNRXConferences/Events
VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Friday, May 16 at 8:30 a.m. U.S. Eastern Time Henderson, Ne
VolitionRx Limited (VNRX) has reported its financial results for Q1 2025, announcing a 44% increase in revenue compared to the same period last year. The company successfully achieved its first revenue from its CE-marked Nu.Q NETs product in Europe and is in discussions with multiple companies for potential licensing agreements. Management aims to match income with expenditures on a cash-basis by the end of 2025. A conference call will take place on May 16 to provide further insights into these developments.
Read more →VNRXConferences/Events
VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update
VolitionRx Limited has announced it will hold its First Quarter 2025 Earnings Conference Call on May 16 at 8:30 a.m. U.S. Eastern Time. The call will cover financial and operational results as well as upcoming milestones. Louise Batchelor, Group Chief Marketing & Communications Officer, along with company executives, will host the call. Additionally, a live audio webcast will be available, and a telephone replay will be accessible until May 30, 2025.
Read more →VNRXGeneral
VolitionRX Limited: Outlines broad strategy to become the
VolitionRX Limited has outlined a strategic plan to commercialize its Nu.Q® NETs product in the human diagnostics market, with a focus on addressing unmet needs in sepsis and coagulation. The company is in discussions with seven major international firms, which collectively have a market value of approximately $600 billion, to license its technology. Furthermore, Volition has already recorded revenue from its CE-marked Nu.Q® NETs product and is seeing interest from numerous hospital networks across Europe. This dual approach aims to leverage existing partnerships while expanding the clinical applications of the product to improve patient care worldwide.
Read more →VNRXGeneral
VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets
VolitionRx Limited is advancing its Nu.Q® platform for human diagnostics, anticipating potential partnerships with over ten companies whose combined market valuation exceeds $600 billion. The company aims to secure multiple licensing agreements in human diagnostics, drawing from its successful veterinary strategies. Ongoing clinical studies show promise in delivering valuable diagnostic solutions for cancer and sepsis, with completed studies supporting the commercialization of its cancer diagnostics products. Volition continues to report positive revenue developments and is focused on expanding its global market presence.
Read more →VNRXConferences/Events
VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Monday, March 31 at 4:30 p.m. U.S. Eastern Time Henderso
VolitionRx Limited has announced its financial results for the fiscal year 2024, reporting a 59% increase in revenue to $1.2 million. The company notably sold approximately 120,000 Nu.Q Vet Cancer Tests and expanded the test's availability globally. Volition achieved significant clinical data to support its products and is in discussions for licensing agreements in the oncology sector. The company aims to reach cash neutrality in 2025, buoyed by recent funding and a strong interest from potential partners.
Read more →VNRXConferences/Events
Volition Announces Two Poster Presentations at ESMO
VolitionRx Limited announced two poster presentations at the European Lung Cancer Congress 2025. The studies demonstrate the potential of their Nu.Q® H3K27Me3 biomarker in enhancing prognosis for patients with Non Small Cell Lung Cancer (NSCLC) when used alongside circulating tumor DNA. Additionally, the Nu.Q® H3.1 immunoassay could identify individuals at high risk for cancer earlier. These presentations aim to showcase advances in epigenetic testing for improved cancer treatment and management decisions.
Read more →VNRXConferences/Events
Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025
VolitionRx Limited (NYSE AMERICAN: VNRX) will host a virtual investor event on April 9, 2025, where key executives will discuss the Nu.Q® cancer diagnostics platform. The event aims to highlight findings from completed independent studies, showcasing the platform's effectiveness in detecting various cancers with low false positive rates. Insights into commercial strategies and the substantial revenue potential in lung cancer diagnostics will also be shared, emphasizing the company's drive for commercialization. A live Q&A session will follow the presentations, allowing for further engagement with investors.
Read more →VNRXGeneral
VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering Up to $2.3 million up front with up to an additional $1.1 million of potential aggregate gross proceeds upon the exercise in full of common st
VolitionRx Limited has announced the pricing of a registered direct offering that could potentially raise up to $2.3 million, with an additional $1.1 million depending on the exercise of share purchase warrants. The offering is set to include shares purchased by both insiders and new investors at an offering price of $0.55 per share. The company plans to utilize the funds raised for research, clinical studies, product commercialization, and general corporate purposes. This offering is being made without a placement agent and is expected to close on or about March 26, 2025, pending customary closing conditions.
Read more →VNRXConferences/Events
VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update
VolitionRx Limited has announced a conference call set for March 31, 2025, to discuss its financial results for the fourth quarter and full fiscal year 2024, alongside a business update. The call will be hosted by key executives, including the President and CFO. VolitionRx is recognized for developing blood tests designed to detect various diseases, including cancers, aiming to enhance patient outcomes through early detection. The event aims to update stakeholders on important happenings and future milestones for the company.
Read more →VNRXGeneral
Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry VolitionRx Limited (NYSE AMERICAN: VNRX) ('Volition'), a multi-national epigenetics company, today announces the results of a study which shows that...
VolitionRx Limited has announced promising results from a study validating its Nu.Q® Cancer immunoassay test, which can accurately detect 21 types of cancer with high specificity. This automated test is positioned to disrupt the liquid biopsy market by potentially reducing the reliance on invasive diagnostics while improving early cancer detection. The company is engaging with multiple large diagnostic firms for licensing agreements, aiming for enhanced accessibility and revenue opportunities. The findings underscore the significance of early detection in improving patient outcomes and managing cancer risks.
Read more →VNRXGeneral
Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer
VolitionRx Limited has announced the release of a new primer titled 'Lung Cancer: Hope of a Brighter Tomorrow,' outlining the potential of its Nu.Q® Cancer assays for improving lung cancer diagnosis, treatment, and monitoring. The report suggests that these assays, which require minimal blood sample size, could enhance early detection and patient journey management. A major study on Non-Small Cell Lung Cancer associated with Next Generation Sequencing is set to be published at the upcoming European Lung Cancer Congress, further supporting their claims. Volition is also in discussions with large diagnostics companies to expand the reach of their cancer testing offerings.
Read more →VNRXConferences/Events
Volition Proudly Sponsors the 44th ISICEM Congress
VolitionRx Limited (NYSE AMERICAN: VNRX) announced its sponsorship of the 44th Annual ISICEM Congress in Brussels, Belgium. The company will feature presentations on their Nu.Q® H3.1 epigenetic screening technology, emphasizing its application in intensive care and emergency medicine. Dr. Andrew Retter, Volition's Chief Medical Officer, highlighted the potential of their research to improve sepsis care and patient outcomes. The congress will attract thousands of participants aiming to enhance intensive care practices.
Read more →VNRXGeneral
Volition Signs first ever Nu.Q® Vet Cancer Test Automation Agreement with Fujifilm Vet Systems
VolitionRx Limited has expanded its supply agreement with Fujifilm Vet Systems to automate the Nu.Q® Vet Cancer Test for use in Japan. The agreement now includes the automation of the test on Fujifilm's i10® platform, aiming for a launch in summer 2025. This partnership highlights the significant demand among Japanese veterinarians for canine cancer screening, as evidenced by over 1,000 hospitals registered to use the test. The automated platform promises to enhance the speed and efficiency of cancer detection in dogs, addressing a critical health concern in veterinary medicine.
Read more →VNRXPhases
Volition Announces First Patient Enrolled in NTU Hospital
VolitionRx Limited has announced the enrollment of its first patient in a clinical trial assessing the Nu.Q® Cancer technology, aimed at distinguishing between malignant and benign pulmonary nodules. This study, conducted in collaboration with National Taiwan University Hospital, is expected to validate prior results indicating the technology's efficacy in accurately identifying cancerous nodules. Completion of the validation study is anticipated by the end of 2025, and positive results may result in the test being adopted in national lung cancer screening efforts. The test could potentially reduce unnecessary procedures and improve early diagnosis of lung cancer, enhancing patient outcomes.
Read more →VNRXPhases
Volition's Nu.Q® Discover Biomarkers to be utilized in Human Clinical Study Sponsored by Leading Pharmaceutical Company for the First Time VolitionRx Limited (NYSE AMERICAN: VNRX) ( Volition ), a multi-national epigenetics company, today announces that it has signed an agreement with a...
VolitionRx Limited has announced a partnership with a leading pharmaceutical company to incorporate its Nu.Q® Discover biomarkers in a Phase 1/2b clinical study. This collaboration is the first of its kind, aiming to measure disease progression and treatment response. Successful completion of the study could result in significant revenue and further studies are anticipated, which may strengthen Volition's position in the pharmaco-epigenetics market. The use of Nu.Q® biomarkers highlights the potential for precision therapy in drug development.
Read more →VNRXConferences/Events
Volition Showcases Nu.Q® Vet Cancer Test at the 97th WVC Annual Conference
VolitionRx Limited will showcase its Nu.Q® Vet Cancer Test at the 97th Annual Western Veterinary Conference in Las Vegas from March 2-5, 2025. The company aims to increase awareness and education about the test, which detects seven common cancers in dogs. Presentations will highlight the test's accessibility and rapid results, enhancing the capabilities of veterinary professionals. The conference is noted for being one of the largest veterinary gatherings in the U.S.
Read more →VNRXGeneral
Volition Signs First Commercial Project Utilizing Rapid High-Throughput Model in the Study of NETosis
VolitionRx Limited has announced its first commercial sale of a High Throughput Synthetic Sepsis method, designed to study Neutrophil Extracellular Traps (NETs) activation in whole blood. The new technology enhances the understanding of NET-related diseases and facilitates the development of new therapeutics. CEO Dr. Jasmine Kway emphasized the importance of this model in overcoming limitations of prior research methods. This innovative approach is expected to advance translational research and contribute significantly to combating conditions like sepsis.
Read more →VNRXConferences/Events
Volition to Host Virtual Investor Event on Nu.Q® NETs, "Casting a New Light on Sepsis Management", on February 14, 2025
VolitionRx Limited will host a virtual investor event on February 14, 2025, focusing on their Nu.Q® NETs biomarker for sepsis management. The event will feature presentations from key company executives, including Dr. Andrew Retter and Gael Forterre, followed by a live Q&A session. The biomarker has shown promise in risk stratification for patients suffering from sepsis. VolitionRx aims to improve patient outcomes through earlier diagnosis and monitoring of critical health conditions.
Read more →VNRXPhases
Large clinical study establishes Nu.Q® NETs H3.1 as an independent predictor of 28-day mortality in sepsis
VolitionRx Limited announced the results of a large clinical study indicating that its Nu.Q® NETs H3.1 biomarker can independently predict 28-day mortality and the need for renal replacement therapy in sepsis patients. The study, involving 971 patients, found that higher levels of this biomarker correlate with more severe organ dysfunction. Researchers highlighted its potential utility for early risk stratification and clinical intervention in critically ill patients. Additionally, the findings support ongoing commercial discussions aimed at integrating Nu.Q® NETs into hospital settings for enhanced sepsis management.
Read more →VNRXGeneral
Volition Issues Business Review 2024
VolitionRx Limited has released its Business Review for 2024, highlighting significant progress and achievements over the past year. The company expanded the availability of its Nu.Q® Vet Cancer Test to 20 countries and sold over 110,000 tests in the first three quarters of 2024. Initiatives included hosting a symposium demonstrating the clinical utility of Nu.Q® NETs in sepsis patients and strengthening the Board of Directors. Additionally, Volition is actively pursuing commercial opportunities in diagnostics for both human and animal health as it prepares for 2025.
Read more →VNRXConferences/Events
VolitionRx Appoints LifeSci Advisors as Investor Relations Consultants
VolitionRx Limited has appointed LifeSci Advisors as its investor relations consultants, aiming to enhance awareness of its products and initiatives. The company is set to participate in the 14th Annual LifeSci Partners Corporate Access Event on January 15th, 2025, coinciding with the J.P. Morgan Health Care Conference. As VolitionRx advances its development of diagnostic tests, it faces various risks outlined in its forward-looking statements, highlighting the uncertainties involved in its growth strategy.
Read more →VNRXPhases
Study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening
VolitionRx Limited announced the results of a study demonstrating that its Nu.Q® Cancer Test can differentiate between malignant and benign nodules detected through Low Dose CT screening. The large-scale study, involving 800 patients, achieved a diagnostic sensitivity of 92% and a Positive Predictive Value of 89%. This test aims to reduce the need for invasive procedures in patients with benign nodules and is poised for further validation in a prospective study at the National Taiwan University Hospital, potentially advancing its integration into national screening programs.
Read more →VNRXGeneral
VolitionRx Announces Pricing of up to $1.9 Million Registered Direct Offering Up to $1.9 million up front with up to an additional $2.7 million of potential aggregate gross proceeds upon the exercise in full of common st
VolitionRx Limited has announced a registered direct offering priced at up to $1.9 million, with the potential for an additional $2.7 million from warrants. The offering is directed towards certain directors, executive officers, and other investors. The company plans to use the proceeds for research and development, clinical studies, and commercialization of blood tests for diseases including cancers. The closing is expected on December 9, 2024, pending customary conditions.
Read more →VNRXConferences/Events
VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Friday, November 15 at 8:30 a.m. U.S. Eastern Time Henderso
VolitionRx Limited announced its third-quarter financial results for 2024, showcasing substantial growth with a 96% year-to-date revenue increase. The company reported sales of over 110,000 Nu.Q Vet Cancer Tests and a significant expansion of its offerings, including access in 17 countries. Additionally, VolitionRx highlighted promising data on its Nu.Q NETs test, which may aid in sepsis management. The upcoming conference call will further discuss their operational progress and future plans.
Read more →VNRXConferences/Events
VolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business Update
VolitionRx Limited has announced a conference call scheduled for November 15, 2024, at 8:30 a.m. Eastern Time to discuss its third quarter 2024 financial results and provide a business update. Key executives will participate to present insights on the company’s recent activities and future milestones. The event will also be accessible via a live audio webcast and will include options for a telephone replay. VolitionRx is committed to advancing epigenetic science to improve disease detection and monitoring.
Read more →VNRXGeneral
Volition Appoints Timothy I. Still as Chairman
VolitionRx Limited has appointed Timothy I. Still as Chairman of its board of directors effective November 6, 2024. With over 35 years in the medical diagnostics sector, Mr. Still brings a wealth of experience from his previous roles, including CEO positions and board memberships across various companies. His appointment is seen as pivotal for Volition, which is focused on developing innovative blood tests for disease detection and monitoring. Executives at Volition believe his leadership will significantly benefit the company's growth and strategic direction.
Read more →VNRXGeneral
Volition Appoints Timothy I. Still as Chairman Henderson, Nevada
VolitionRx Limited has appointed Timothy I. Still as the Chairman of its Board of Directors, effective November 6, 2024. Mr. Still has over 35 years of experience in the medical diagnostics sector and previously served as President and CEO of Sense Biodetection. His expertise is anticipated to foster strategic growth and commercial viability for Volition, especially as the company focuses on developing innovative diagnostic technologies. Volition aims to enhance healthcare outcomes through their specialized blood tests for various diseases.
Read more →VNRXConferences/Events
Multiple studies show Nu.Q® NETs test could predict sepsis patients at risk of deteriorating
VolitionRx Limited announced findings from a symposium on the Nu.Q® NETs test, revealing its potential to predict sepsis patients at risk of deterioration. The research included three independent studies with over 3,000 patients, highlighting that elevated levels of circulating H3.1 nucleosomes correlate with increased mortality and organ failure risks. Experts believe using this test could change the management of sepsis, improving patient outcomes. Volition plans to commercialize the Nu.Q® NETs test, leveraging these findings in licensing discussions with industry stakeholders.
Read more →VNRXConferences/Events
Volition to share new
VolitionRx Limited (NYSE AMERICAN: VNRX) will present new data at a webinar regarding its Nu.Q® NETs technology, which aims to enhance sepsis management. The findings are based on three independent studies with over 3,000 patients. The webinar, taking place on October 21, will include insights from key executives on the potential clinical applications of the technology. However, Volition faces various challenges, including regulatory hurdles and competition in the diagnostics market.
Read more →VNRXConferences/Events
Volition hosts NETs in sepsis management symposium at ESICM Lives 2024
VolitionRx Limited is hosting a symposium at ESICM Lives 2024 in Barcelona to discuss the use of its Nu.Q® NETs technology in sepsis management. The symposium will feature expert presentations on large independent studies showcasing the potential clinical utility of the Nu.Q® NETs H3.1 assay as a diagnostic tool for sepsis. Elevated levels of H3.1 nucleosomes could revolutionize treatment strategies, aiming to improve early detection and monitoring of this critical condition. The event is expected to gather leading researchers and clinicians from around the world to share insights and findings on this important topic.
Read more →VNRXGeneral
Volition Appoints Dr. Ethel Rubin as an Independent Director Henderson, Nevada
VolitionRx Limited has appointed Dr. Ethel Rubin as an independent director and member of the Audit and Compensation Committees, effective September 30, 2024. Dr. Rubin has extensive experience in the life sciences sector, contributing to the launch of numerous commercial products and holding key leadership positions in various organizations. Her appointment is seen as a strategic move to enhance Volition's efforts in commercializing its epigenetic solutions, particularly its Nu.Q technology, which has potential applications in both animal and human health. Volition aims to advance diagnostic and monitoring solutions for major diseases.
Read more →VNRXConferences/Events
Volition Hosts KOL Roundtable on Sepsis
VolitionRx Limited hosted a Key Opinion Leader roundtable in Paris focused on improving sepsis management through their Nu.Q® NETs technology. This event gathered leading experts in sepsis to discuss research findings and the technology's potential to predict organ failure and enhance patient outcomes. The roundtable emphasized the importance of early detection in reducing mortality rates and the long-term effects of sepsis on survivors. Volition plans to share more findings at an upcoming symposium in Barcelona.
Read more →VNRXConferences/Events
VolitionRx Limited Announces Second Quarter 2024 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Thursday, August 15 at 8:30 a.m. U.S. Eastern Time Henders
VolitionRx Limited announced its financial results for the second quarter of 2024, showing an 83% increase in revenue compared to the same period last year, reaching $396,000. The company also reported the sale of over 60,000 Nu.Q Vet Cancer Tests in the first half of the year, indicating strong market interest. To strategize further growth, VolitionRx plans to negotiate licensing deals, leveraging support from an advisory company. A conference call is scheduled for August 15, 2024, to provide more insights into the operational and financial results.
Read more →VNRXGeneral
VolitionRx Announces Pricing of up to $21.5 Million Registered Direct Offering $7 million upfront with up to an additional $14.5 million of potential aggregate gross proceeds upon the exercise in full of milestone-linked
VolitionRx Limited announced a registered direct offering of up to $21.5 million, which includes $7 million upfront and an additional $14.5 million from milestone-linked warrants. The offering, expected to close around August 12, 2024, involves the sale of 12,727,273 shares of common stock at an offering price of $0.55 per share. The proceeds will primarily be used for research and product development. H.C. Wainwright & Co. is the exclusive placement agent for this offering.
Read more →VNRXConferences/Events
VolitionRx Limited Schedules Second Quarter 2024 Earnings Conference Call and Business Update
VolitionRx Limited has scheduled a conference call for August 15, 2024, at 8:30 a.m. U.S. Eastern Time to discuss its financial and operational results for the second quarter of 2024. During the call, executives, including the CEO and Chief Financial Officer, will provide updates on significant events and milestones achieved in the past quarter. The company is concentrating on blood tests aimed at diagnosing and monitoring diseases, which could lead to improved patient outcomes.
Read more →VNRXGeneral
Volition appoints PharmaVentures for Capture PCR™ and oncology portfolio licensing
VolitionRx Limited has appointed PharmaVentures Ltd to advise on the licensing of its oncology portfolio, including innovative blood tests for cancer detection and monitoring. PharmaVentures will leverage its extensive network and experience to help Volition secure key licensing deals. The company is enthusiastic about the potential of its epigenetic technologies to enhance patient outcomes. However, the success of Volition's plans depends on various uncertainties, including regulatory approvals and market acceptance.
Read more →VNRXGeneral
VolitionRx Limited Issues Mid-Year Review Ahead of 2024 Annual Meeting Henderson, Nevada
VolitionRx Limited has issued a mid-year review, highlighting key achievements as it prepares for its upcoming Annual Meeting. The company has expanded its Nu.Q Vet Cancer Test to 15 countries and is engaged in discussions for licensing opportunities in the IVD and oncology sectors. CEO Cameron Reynolds noted significant progress in their testing technologies and aims to negotiate licensing deals for their human diagnostics products. However, the company faces challenges related to regulatory approvals and competition in the diagnostic market.
Read more →VNRXConferences/Events
VolitionRx Limited to Present at Jefferies Global Healthcare Conference
VolitionRx Limited (VNRX) announced its participation at the Jefferies Global Healthcare Conference, with CEO Cameron Reynolds to present their innovative epigenetic technologies. Scheduled for June 5, 2024, the presentation aims to highlight the company's efforts in improving outcomes for patients with diseases like sepsis and cancer through earlier detection and monitoring. Attendees can arrange one-on-one meetings with Volition's executive team to learn more about their advancements in diagnostic testing.
Read more →VNRXConferences/Events
VolitionRx Limited Announces First Quarter 2024 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Tuesday, May 14 at 8:30 a.m. U.S. Eastern Time Henderson, N
VolitionRx Limited announced its financial results for the first quarter of 2024, showcasing a 15% revenue increase year-over-year. The company plans a conference call to discuss these updates and upcoming milestones. Volition aims to achieve cash flow neutrality by 2025 through revenue growth and non-dilutive funding. However, the revenue growth from its Nu.Q Vet product line is slower than expected, prompting the company to implement cost reduction strategies.
Read more →VNRXConferences/Events
VolitionRx Limited Schedules First Quarter 2024 Earnings Conference Call and Business Update
VolitionRx Limited has announced a conference call scheduled for May 14, 2024, at 8:30 a.m. U.S. Eastern Time. The call will discuss the company's financial and operational results for the first quarter of 2024, as well as provide a business update. Key executives will be participating, including the President and Group CEO, along with senior finance and medical officers. This event reflects Volition's commitment to transparent communication regarding its progress in epigenetics and disease diagnostics.
Read more →VNRXGeneral
Nu.Q® Vet Cancer Test launched in-clinic in U.S. and Europe through Antech
VolitionRx Limited has launched its Nu.Q® Vet Cancer Test in-clinic for veterinarians in the U.S. and Europe through a partnership with Antech. This new test allows for rapid, accurate cancer screening of high-risk breeds, particularly older dogs, delivering results in approximately six minutes. The initiative aims to improve timely cancer detection, assisting veterinarians and pet owners in making informed decisions about cancer care. Volition emphasizes that this rollout represents a significant step towards making their epigenetic technology accessible and affordable globally.
Read more →VNRXConferences/Events
VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Tuesday, March 26 at 8:30 a.m. U.S. Eastern Time Henders
VolitionRx Limited reported its full fiscal year 2023 financial results, showcasing a notable increase in revenue of 153% to approximately $775,000. The company highlighted the successful launch of its Nu.Q Vet Cancer Test with over 58,000 kits sold and new partnerships established, including one with Fujifilm Vet Systems. Volition's executives expressed optimism for future growth, mentioning plans for a conference call to discuss results in detail. The firm also noted significant progress in its cancer detection technology, Capture-PCR, which was recently presented at a major medical conference.
Read more →VNRXConferences/Events
VolitionRx Limited Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call and Business Update
VolitionRx Limited has scheduled a conference call for March 26, 2024, to discuss its financial and operational results for the fourth quarter and full year of 2023. This call will also include a business update and will feature key executives from the company. The event highlights Volition's ongoing commitment to advancing epigenetics, including the development of cost-effective blood tests for early diagnosis and monitoring of various diseases.
Read more →VNRXGeneral
Volition and Fujifilm Vet Systems Launch Nu.Q® Vet Cancer Test in Japan
VolitionRx Limited has entered into a supply agreement with Fujifilm Vet Systems to launch the Nu.Q® Vet Cancer Test for dogs in Japan. This collaboration allows Fujifilm Vet Systems to provide cancer screening services through its network of laboratories across the country. The test aims to facilitate early cancer detection and improve veterinary patient care. Volition expresses optimism about expanding its market presence in Asia and enhancing its offerings in veterinary diagnostics.
Read more →VNRXGeneral
Volition appoints Dr Andrew Retter as Chief Medical Officer Henderson, Nevada
VolitionRx Limited has appointed Dr Andrew Retter as Chief Medical Officer, effective April 1, 2024. Dr Retter, an expert in Intensive Care Medicine and Haematology, has been working with Volition in an advisory role since January 2022. His role will involve providing medical leadership to align the company's scientific and clinical efforts with patient needs. This appointment is seen as a significant step in Volition's aim to advance diagnostic solutions to improve patient outcomes.
Read more →VNRXConferences/Events
Volition to Share Nu.Q® NETs Strategy Update at Upcoming Webinar
VolitionRx Limited is set to participate in a webinar on February 13, 2024, to discuss recent advancements and ongoing studies related to its Nu.Q® NETs test for sepsis. The event will feature updates from key company executives and is aimed at increasing stakeholder awareness about the challenges of sepsis diagnosis and treatment. Additionally, the company will outline its future plans towards commercialization of its diagnostic technologies.
Read more →VNRXGeneral
Volition Issues Business Review 2023
VolitionRx Limited has released its Business Review for 2023, highlighting notable achievements including the successful launch of the Nu.Q® Vet Cancer Test and completing the Q-Sub process with the FDA for Nu.Q® NETs. The company aims to enhance global access to its tests and has made significant advancements in early cancer detection methods. Volition's strategic initiatives are poised to strengthen its position in the diagnostics market. Despite these accomplishments, the company faces challenges such as market acceptance and competition in a rapidly evolving industry.
Read more →VNRXGeneral
VolitionRx Secures Approximately $5.5 Million in Belgium Regional Government Financing from Wallonie Entreprendre Henderson, Nevada
VolitionRx Limited has secured approximately $5.5 million in financing from Wallonie Entreprendre in Belgium to advance its Nu.Q product portfolio. The funding includes both an unsecured loan and a private placement of common stock. The proceeds will be used to further develop their diagnostic products aimed at early disease detection, particularly for conditions such as sepsis. While this support is a positive step for VolitionRx, the company faces challenges including competition and the successful commercialization of their products.
Read more →VNRXConferences/Events
Volition Presents at the 5th Annual Congress of the International Liquid Biopsy Society
VolitionRx Limited is set to present at the 5th Annual Congress of the International Liquid Biopsy Society in Madrid, Spain. During the event, Dr. Jake Micallef will discuss a novel cancer detection method that allows for the physical isolation of tumor-derived circulating DNA from blood samples. This innovative technique has shown strong results in initial clinical tests, successfully detecting various cancers, including early-stage leukemia and colorectal cancer. Volition's focus on enhancing early cancer detection aims to improve patient outcomes significantly.
Read more →VNRXConferences/Events
VolitionRx Limited Announces Third Quarter 2023 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Wednesday, November 15, at 8:30 a.m. U.S. Eastern Time Hend
VolitionRx Limited announced its financial results for Q3 2023, highlighting significant revenue growth for its Nu.Q Vet Cancer Test, which increased nearly five-fold over the previous year. The company reported a total revenue of $531,000 for the year-to-date, representing a 185% rise from 2022. Additionally, Volition completed the FDA's Q-Sub process, affirming a traditional regulatory pathway for its innovative cancer detection method. The firm continues to expand its market presence, including recent launches in the UK and Ireland, and anticipates accelerating revenue growth into 2024.
Read more →VNRXConferences/Events
VolitionRx Limited Schedules Third Quarter 2023 Earnings Conference Call and Business Update
VolitionRx Limited has announced a conference call scheduled for November 15, 2023, to discuss its financial and operational results for the third quarter of 2023. The call will include an update on important events from the quarter and upcoming milestones, featuring key executives from the company. A live audio webcast of the call will also be accessible on Volition's investor relations page, with replay options available until November 29, 2023.
Read more →VNRXGeneral
Volition and VPG Launch Nu.Q® Vet Cancer Test in UK & Ireland
VolitionRx Limited and the Veterinary Pathology Group have partnered to launch the Nu.Q® Vet Cancer Test across veterinary practices in the UK and Ireland. This innovative blood test aims for early detection and monitoring of cancer in dogs, particularly benefiting older dogs and breeds with higher cancer risks. The test can be easily integrated into standard veterinary procedures, enhancing preventive care and potentially improving treatment outcomes for pets. This initiative underscores both organizations' commitment to advancing animal healthcare.
Read more →VNRXConferences/Events
Volition Presents Breakthrough Liquid Biopsy Blood Test Method for Early-stage Cancer
VolitionRx Limited has announced the introduction of a groundbreaking cancer detection method at ESMO 2023, which focuses on the physical isolation of tumor-derived circulating tumor DNA (ctDNA) fragments from blood samples. This novel liquid biopsy technique enables faster and more cost-effective cancer detection compared to existing methods. Early results from clinical experiments demonstrated high accuracy in identifying various cancers, including leukemia and colorectal cancer, at early stages. The company is optimistic about developing additional cancer-specific assays to improve detection further.
Read more →VNRXPhases
Measuring Nucleosomes Using Nu.Q® NETs is a Promising Biomarker for Septic Shock
VolitionRx Limited announced a study validating its Nu.Q® NETs test as a promising biomarker for evaluating disease severity in septic shock patients. Led by Professor Guillaume Monneret, the research demonstrated significant correlations between elevated nucleosome levels and both severity indicators and mortality risk. The findings emphasize the test's potential in supporting sepsis prognosis, providing hope for improved patient outcomes. Concerns about market acceptance and the need for more extensive validation studies were also noted.
Read more →VNRXGeneral
US Ambassador Adler visits Belgian Volition
U.S. Ambassador Michael M. Adler visited VolitionRx Limited's facilities in Belgium, where the company develops blood tests for various diseases, including some cancers. The COO of Volition, Gaetan Michel, praised the collaborative efforts between U.S. and Belgian stakeholders over 13 years, emphasizing their innovative technology and patient care. Volition continues to expand its reach with ongoing research and a focus on improved diagnostics, underlining the importance of international partnerships in enhancing patient outcomes.
Read more →VNRXConferences/Events
Volition Presents Three Cancer Detection Abstracts at ESMO 2023
VolitionRx Limited is set to present three significant abstracts at ESMO 2023, focusing on innovative cancer detection techniques. Among the presentations will be new data regarding lung cancer and glioblastoma. Dr. Dorian Pamart will showcase a novel detection method for plasma cfDNA fragments, while Dr. Pei-Hsing Chen will differentiate between malignant and benign lung nodules. In collaboration with the University of Namur, a study on nucleosome-based biomarkers for glioblastoma will also be presented.
Read more →VNRXConferences/Events
Volition Publishes Key Opinion Leader Roundtable Report on NETs in Sepsis
VolitionRx Limited has published a report from its Key Opinion Leader roundtable on sepsis management, discussing the use of its Nu.Q® NETs technology. The roundtable included prominent medical experts who acknowledged the potential for this technology in enhancing diagnosis, treatment guidance, and personalized medicine for sepsis patients. VolitionRx aims to improve patient outcomes through its innovative diagnostic solutions, while also considering areas for future research in the field.
Read more →VNRXConferences/Events
Volition to Reveal New Cancer Detection Method Insights at Upcoming Webinar
VolitionRx Limited (VNRX) will present new insights into its cancer detection methods during an upcoming webinar on October 26, 2023. Hosted by Edison Group, the event features discussions led by key members of Volition’s scientific team, including Dr. Jake Micallef. Stakeholders are expected to gain valuable information about Volition's innovative approaches in early cancer detection and the commercialization of its proposed tests. The data to be discussed is also anticipated to be shared at the ESMO 2023 congress, marking an important development in the field of oncology diagnostics.
Read more →VNRXConferences/Events
Volition Hosts Key Opinion Leader Roundtable on Sepsis Management
VolitionRx Limited is hosting a Key Opinion Leader roundtable in Athens focused on sepsis management. Chaired by Professor Djillali Annane, the event will address the challenges of sepsis, the role of Neutrophil Extracellular Traps (NETs), and the potential clinical use of Volition's Nu.Q® NETs technology. Esteemed professionals from various specialisms will collaborate to explore personalized care approaches and improve diagnostic tool integration into clinical practice. The event coincides with Sepsis Awareness Month, aiming to raise awareness about the disease, which is a leading cause of hospital deaths globally.
Read more →VNRXConferences/Events
VolitionRx Limited Announces Second Quarter 2023 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Tuesday, August 15, at 8:30 a.m. U.S. Eastern Time Henders
VolitionRx Limited reported its second quarter financial results for 2023, showcasing significant progress in its business, including a Breakthrough Device Designation Request submitted to the FDA for its Nu.Q technology related to sepsis. The company announced total revenue of $366,000 for the first half of 2023, exceeding the full year revenue of 2022, driven by robust sales of its Nu.Q Vet Cancer Test. Volition also outlined future plans including reaching global markets for its canine cancer screening tests and increased collaborations in Europe. A conference call to discuss these developments is scheduled for August 15, 2023.
Read more →VNRXConferences/Events
VolitionRx Limited Schedules Second Quarter 2023 Earnings Conference Call and Business Update
VolitionRx Limited has scheduled a conference call for August 15, 2023, to discuss its second quarter 2023 financial and operating results, alongside business updates. CEO Cameron Reynolds and other executives will present, highlighting important developments and future milestones for the company. Additionally, a live audio webcast will be available for interested investors. VolitionRx is focused on developing blood tests for early disease diagnosis and monitoring.
Read more →VNRXGeneral
VolitionRx Limited Announces Exercise of Over-Allotment Option by Underwriters
VolitionRx Limited announced that underwriters have exercised an over-allotment option in its public offering, resulting in the sale of an additional 1,950,000 shares. This move increases the gross proceeds from the offering to approximately $19.0 million. The company plans to use the proceeds for research, product development, and potential acquisitions, focusing on improving diagnostic capabilities for several diseases. The exercise of the over-allotment option closed on June 23, 2023.
Read more →VNRXGeneral
VolitionRx Limited Announces Closing of $16.5 Million Underwritten Public Offering of Common Stock
VolitionRx Limited announced the closing of a $16.5 million underwritten public offering of its common stock. The company plans to use the net proceeds for research, product development, clinical studies, commercialization, and working capital. The offering was managed by Freedom Capital Markets and Bancroft Capital, and aligns with Volition's efforts in developing cost-effective blood tests for various diseases, leveraging their proprietary nucleosome quantification platform.
Read more →VNRXGeneral
VolitionRx Limited Announces Pricing of $16.5 Million Underwritten Public Offering of Common Stock
VolitionRx Limited has announced the pricing of a public offering of 13 million shares of common stock at $1.27 per share, aiming to raise $16.5 million before fees. The funds are intended for research, development, and potential acquisitions to enhance product commercialization. The offering is set to close around June 5, 2023, subject to customary closing conditions. The company has also granted underwriters an option to purchase additional shares to cover over-allotments.
Read more →VNRXGeneral
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock
VolitionRx Limited has announced a proposed underwritten public offering of its common stock to raise funds for research, clinical studies, and product commercialization. The company will offer a 30-day option for underwriters to purchase additional shares. While the offering aims to support Volition's growth in developing innovative diagnostic tests, there are uncertainties about market conditions and the final terms of the offering. The use of proceeds includes working capital and potential acquisitions to further enhance product development.
Read more →VNRXGeneral
Volition Study shows Nucleosome Concentrations are a useful tool for Canine Cancer Treatment Monitoring
VolitionRx Limited announced a study indicating that plasma nucleosome concentrations serve as a valuable metric for monitoring treatment and disease progression in dogs with hematopoietic cancers. Conducted at Texas A&M University, the research found that elevated nucleosome levels correlate with disease severity and are particularly useful in assessing treatment response. This advancement could enhance the management of canine lymphoma and other related cancers through improved tracking mechanisms.
Read more →VNRXConferences/Events
VolitionRx Limited Announces First Quarter 2023 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Thursday, May 11, at 8:30 a.m. U.S. Eastern Time Henderson,
VolitionRx Limited reported its financial results for the first quarter of 2023, showcasing significant growth with a 381% increase in sales for its Nu.Q Vet Cancer Test. The company has entered into supply agreements with prominent industry players, enhancing its revenue potential. VolitionRx is also progressing towards the commercialization of its Nu.Q NETs test, with large-scale studies underway to support its FDA application. The company will discuss these updates in an upcoming conference call and Capital Markets Day, reinforcing its commitment to advancing cancer diagnostics.
Read more →VNRXConferences/Events
VolitionRx Limited Schedules First Quarter 2023 Earnings Conference Call and Business Update
VolitionRx Limited announced a conference call scheduled for May 11, 2023, to discuss its first quarter financial results and provide a business update. The call will be hosted by key executives and will also include details about the company's Capital Markets Day on the same date. VolitionRx is developing innovative blood tests to help diagnose serious diseases, leveraging its proprietary Nu.Q® platform.
Read more →VNRXConferences/Events
VolitionRx Limited to Host Capital Markets Day at the NYSE on Thursday May 11.
VolitionRx Limited is set to host a Capital Markets Day on May 11, 2023, at the NYSE. This hybrid event will include presentations from the executive team and notable experts in medicine, discussing corporate and commercial strategies, and clinical evidence. Attendees can join in-person or virtually, with the event aimed at informing investors about the latest developments in the company's healthcare solutions. The company specializes in epigenetics, particularly the Nu.Q technology used for diagnosing diseases.
Read more →VNRXConferences/Events
VolitionRx Limited Announces Full Fiscal Year 2022 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Thursday, March 16, at 8:30 a.m. U.S. Eastern Time Execu
VolitionRx Limited announced its full fiscal year 2022 financial results, showcasing significant achievements such as securing global agreements with Heska and IDEXX for their Nu.Q Vet Cancer Test. The company reported a 240% increase in revenue compared to the previous year. Additionally, Volition received a CE Mark for its Nu.Q NETs product, facilitating broader clinical use. Despite these positive developments, the company noted high operational cash usage and a modest overall cash position, signaling ongoing financial challenges.
Read more →VNRXConferences/Events
VolitionRx Limited Schedules Full Year 2022 Earnings Conference Call and Business Update
VolitionRx Limited has announced a conference call scheduled for March 16, 2023, where it will discuss its financial results for the full fiscal year 2022 and provide a business update. The call will feature key executives, including Cameron Reynolds, the President and CEO. During the call, the company is expected to address significant events from 2022 and outline upcoming milestones. The conference will also be accessible via a live audio webcast and will have a telephone replay available until March 30, 2023.
Read more →VNRXGeneral
VolitionRx Limited Announces Closing of $8.7 Million Underwritten Public Offering of Common Stock
VolitionRx Limited announced the completion of its public offering, raising approximately $8.7 million from the sale of 4,945,000 shares of common stock at $1.75 each. The company plans to allocate the funds towards research, continued product development, clinical studies, and working capital. The offering was managed by Newbridge Securities Corporation, and the shares were issued under an SEC registration statement. Volition is focused on developing cost-effective blood tests for various diseases, facilitated by its Nu.Q® platform.
Read more →VNRXGeneral
VolitionRx Limited Announces Pricing of $7.525 Million Underwritten Public Offering of Common Stock
VolitionRx Limited has announced the pricing of an underwritten public offering of 4,300,000 shares of its common stock priced at $1.75 per share, which is expected to yield gross proceeds of $7.525 million. The company plans to utilize the proceeds for various activities including research and development, clinical studies, and working capital needs. Additionally, Volition has granted an option to the underwriter to purchase more shares, indicating a strategic approach to managing investor interest. The offering is anticipated to close on or about February 22, 2023, pending customary closing conditions.
Read more →VNRXGeneral
Volition's Nu.Q® Vet Cancer Test Now Available for Pre-Order at The Point-of-Care Through Heska Corporation VolitionRx Limited (NYSE American: VNRX) ( Volition ), a multi-national epigenetics company, announces its Nu.Q® Vet Cancer Test is now available for ...
VolitionRx Limited has announced that its Nu.Q® Vet Cancer Test is now available for pre-order at the point-of-care through Heska Corporation. This test allows veterinarians to detect canine cancer quickly and affordably, enabling earlier intervention for pets. The Nu.Q® test will be highlighted at the 2023 Western Veterinary Conference in Las Vegas, marking a significant advancement as it is the first instance of the test being offered outside of centralized laboratory settings. The commercial launch is planned for early in the second quarter of 2023.
Read more →VNRXConferences/Events
Volition to Take Part in Nu.Q® Vet Commercial Strategy Webinar
VolitionRx Limited is set to participate in a webinar focused on their Nu.Q® Vet commercial strategy, scheduled for January 26, 2023. Key executives, including CEO Dr. Tom Butera, will provide updates on the Nu.Q® Vet Cancer Test, designed for early detection of cancer in dogs. The webinar comes after a report detailing pet health opportunities related to Volition's innovations. The company is optimistic about its ventures in the companion animal healthcare sector, aiming to capitalize on significant market prospects.
Read more →VNRXGeneral
Volition Announces Expansion of Availability of the Nu.Q® Vet Cancer Test Through IDEXX
VolitionRx Limited has announced the expansion of its Nu.Q® Vet Cancer Test availability through IDEXX Laboratories' reference laboratory network in the U.S. This test facilitates early cancer detection in older or at-risk dogs and is intended to support veterinarians in making clinical decisions. The launch aligns with Volition's strategy to commercialize its Nucleosomics™ technology in companion animal healthcare, aiming to leverage IDEXX's global network for broader customer access. This initiative is expected to address the significant segment of the market where nearly 50% of dogs over 10 years old develop cancer.
Read more →VNRXGeneral
Volition Issues Business Review 2022
VolitionRx Limited has released its Business Review for 2022, highlighting significant milestones as the company shifts from research and development to commercial operations. Key achievements include expanding availability of the Nu.Q® Vet Cancer Test and obtaining a CE mark for Nu.Q® NETs. The company is optimistic about 2023, anticipating further growth and commercialization of its diagnostic products. Volition focuses on developing cost-effective blood tests for monitoring life-altering diseases, including cancer.
Read more →VNRXConferences/Events
VolitionRx Limited Announces Third Quarter 2022 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Tuesday, November 15, at 8:30 a.m. U.S. Eastern Time Hender
VolitionRx Limited Announces Third Quarter 2022 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for
Tuesday, November 15, at 8:30 a.m. U.S. Eastern Time
Henderson, Nevada, November 14, 2022 /PRNewswire/ -- VolitionRx
Read more →VNRXGeneral
Volition Announces Clinical Research Study with Oncovet
HENDERSON, Nev., Nov. 14, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced a clinical research study with Oncovet, a renowned veterinary referral clinic, specializing in medical and radiation oncology.
Read more →VNRXConferences/Events
Volition to Participate in a Lung Cancer Screening Study in France
HENDERSON, Nev., Nov. 10, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has been invited to participate in a government-backed prospective study to evaluate the performance of blood biomarkers in the early detect
Read more →VNRXConferences/Events
VolitionRx Limited Schedules Third Quarter 2022 Earnings Conference Call and Business Update
Conference call to take place on Tuesday November 15 at 08:30 a.m. Eastern Time
HENDERSON, Nev., Nov. 9, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Tuesday November 15 at 08.30 a.m. Eastern Time to
Read more →VNRXGeneral
Volition Announces the Launch of the Nu.Q® Vet Cancer Screening Test in the U.S. and Europe Through Heska
HENDERSON, Nev., Nov. 3, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the launch of its Nu.Q® Vet Cancer Screening Test across the U.S. and the forthcoming launch in Europe by Heska Corporation (NASDAQ
Read more →VNRXGeneral
Volition Signs Global Supply Agreement for Nu.Q® Vet Cancer Test
HENDERSON, Nev., Oct. 20, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the signing of a global supply agreement with a market leader in pet healthcare (the "Company").
Through Volition's supply agreem
Read more →VNRXGeneral
Volition Appoints Mickie Henshall as an Independent Director Henderson, Nevada
vnrx_ex991.htm EXHIBIT 99.1
Volition Appoints Mickie Henshall as an Independent Director
Henderson, Nevada, August 16, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE: VNRX) ("Volition"), a multi-national epigenetics company, has announced the appointment of Mickie Henshall to it
Read more →VNRXConferences/Events
VolitionRx Limited Announces Second Quarter 2022 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Thursday, August 11, at 8:30 a.m. U.S. Eastern Time Hender
vnrx_ex991.htm EXHIBIT 99.1
VolitionRx Limited Announces Second Quarter 2022 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for
Thursday, August 11, at 8:30 a.m. U.S. Eastern Time
Henderson, Nevada, August 10, 2022
Read more →VNRXPhases
Volition Announces U.S. Clinical Study for NETs
HENDERSON, Nev., Aug. 10, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced a sponsored research agreement with The University of Texas MD Anderson Cancer Center to evaluate the role of neutrophil extra
Read more →VNRXConferences/Events
VolitionRx Limited Schedules Second Quarter 2022 Earnings Conference Call and Business Update
Conference call to take place on Thursday August 11 at 08:30 a.m. Eastern Time
HENDERSON, Nev., Aug. 8, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Thursday August 11, at 08.30 a.m. Eastern Time to
Read more →VNRXFDA Updates
Volition Appoints DXOCRO to Spearhead U.S. FDA Strategy
HENDERSON, Nev., Aug. 8, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Diagnostic Oncology CRO, LLC ("DXOCRO") to undertake development and clinical validation studies for its Nu.Q® product portfoli
Read more →VNRXGeneral
VolitionRx Awarded $1.5 Million in Non-Dilutive Funding
HENDERSON, Nev., Aug. 3, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced it has been awarded a further $1.5 million non-dilutive funding from Namur Invest Capital Risk in Belgium.
Namur Invest's awar
Read more →VNRXGeneral
VolitionRx Limited Announces Closing of $6.9 Million Underwritten Public Offering of Common Stock
HENDERSON, Nev., Aug. 2, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced today the closing of its previously announced underwritten public offering of 3,450,000 shares of its common stock, including the e
Read more →VNRXGeneral
VolitionRx Limited Announces Pricing of $6 Million Underwritten Public Offering of Common Stock
HENDERSON, Nev., July 29, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced today the pricing of its underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $2.00
Read more →VNRXConferences/Events
New NETs Data Presented at International Society on Thrombosis and Haemostasis (ISTH) Congress
HENDERSON, Nev., July 13, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, in collaboration with researchers at the University of Namur and QUALIblood in Belgium has published a poster presentation entitled "Evaluat
Read more →VNRXGeneral
Volition Achieves CE Mark for Nu.Q® NETs Test
to aid the detection and evaluation of diseases associated with NETosis
AUSTIN, Texas, May 31, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced that its Nu.Q® NETs test has been CE marked for the dete
Read more →VNRXConferences/Events
VolitionRx Limited Announces First Quarter 2022 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Thursday, May 12, at 8:30 a.m. U.S. Eastern Time
vnrx_ex991.htm EXHIBIT 99.1
VolitionRx Limited Announces First Quarter 2022 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for
Thursday, May 12, at 8:30 a.m. U.S. Eastern Time
AUSTIN, Texas, May 11, 2022 /PRNewswir
Read more →VNRXConferences/Events
VolitionRx Limited Schedules First Quarter 2022 Earnings Conference Call and Business Update
Conference call to take place on Thursday May 12 at 08:30 a.m. Eastern Time
Capital Markets Day Friday May 13 at 10:00 a.m. Eastern Time
AUSTIN, Texas, May 6, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference ca
Read more →VNRXGeneral
VolitionRx Limited to Host Capital Markets Day on Friday May 13
AUSTIN, Texas, May 5, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") a multi-national epigenetics company plans to host a Capital Markets Day in a hybrid format on Friday, May 13, 2022, at 10 a.m. U.S. Eastern Time. Volition's executive team will provi
Read more →VNRXGeneral
Volition Launches its Nu.Q® Vet Cancer Test in Asia Through its Appointed Distributor SAGE Healthcare
AUSTIN, Texas, April 25, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose and monitor a range of cancers and other life-altering diseases in
Read more →VNRXConferences/Events
VolitionRx Limited Announces Full Fiscal Year 2021 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Thursday, March 31, at 8:00 am U.S. Eastern Time Execute
vnrx_ex991.htm EXHIBIT 99.1
VolitionRx Limited Announces Full Fiscal Year 2021 Financial
Results and Business Update
Conference call to discuss financial and operational results scheduled for
Thursday, March 31, at 8:00 am U.S. Eastern Time
Executed global licensing and sup
Read more →VNRXGeneral
Volition Signs Exclusive $28 million License and Supply Agreement with Heska Corporation to Distribute Nu.Q Vet Cancer Screening Test at the Point of Care
vnrx_ex991.htm EXHIBIT 99.1
Volition Signs Exclusive $28 million License and Supply Agreement
with Heska Corporation to Distribute Nu.Q Vet Cancer Screening
Test at the Point of Care
AUSTIN, Texas, March 29, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Voli
Read more →VNRXConferences/Events
Volition presents study data at ASCO GI 2022 on circulating nucleosomes for the detection of colorectal cancer and high-risk advanced adenomas
AUSTIN, Texas, Jan. 20, 2022 /PRNewswire/ --VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced the results of two large scale clinical studies, which show that the company's Nu.Q® assays, when used in conjunction with the Fe
Read more →VNRXGeneral
Volition Executes its First Supply and Licensing Contract for its Nu.Q® Vet Cancer Screening Test in Asia
SAGE Healthcare Private Limited appointed to serve as a non-exclusive licensee and distributor for Volition's Nu.Q® Vet Cancer Screening Test in centralized labs in Singapore, with launch planned in Singapore in the first quarter of 2022 followed by expansion in conjunction with
Read more →VNRXConferences/Events
VolitionRx Limited Announces Third Quarter 2021 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Thursday, November 11, at 8:00 a.m. U.S. Eastern Time Healt
vnrx_ex991.htm EXHIBIT 99.1
VolitionRx Limited Announces Third Quarter 2021 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for
Thursday, November 11, at 8:00 a.m. U.S. Eastern Time
Healthy balance sheet with appro
Read more →VNRXConferences/Events
VolitionRx Limited Schedules Third Quarter 2021 Earnings Conference Call and Business Update
AUSTIN, Texas, Nov. 8, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Thursday, November 11, at 8:00 a.m. Eastern time to discuss its financial and operating results for the third quarter of 2021, in ad
Read more →VNRXConferences/Events
Volition Veterinary Presents Two Posters at the 2021 Veterinary Cancer Society Conference
Positive data show Nu.Q® can be used to monitor for disease response and progression including remission monitoring in cancer bearing dogs.
Paves the way for second Nu.Q® Vet product launch planned for 2022.
A second abstract details the first use of Nu.Q® Capture, Volition's e
Read more →VNRXConferences/Events
VolitionRx Limited Announces Second Quarter 2021 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Thursday, August 12, at 8:00 a.m. U.S. Eastern Time Strong
vnrx_ex991.htm EXHIBIT 99.1
VolitionRx Limited Announces Second Quarter 2021 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for
Thursday, August 12, at 8:00 a.m. U.S. Eastern Time
Strong balance sheet with approxi
Read more →VNRXGeneral
Volition's Nu.Q® NETs Assay Demonstrates Promising Results in COVID-19 Risk Stratification and Disease Monitoring VolitionRx Limited (NYSE AMERICAN: VNRX) ( Volition ), a multi-national epigenetics company developing simple, easy to use, cost effective blood...
AUSTIN, Texas, July 22, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, h
Read more →VNRXGeneral
VolitionRx Limited Announces First Quarter 2021 Financial Results and Business Update
Secured strongest-ever balance sheet with approximately $33.1 million in cash
Strengthened the Company's leadership team to drive commercial focus
Expanded the Company's intellectual property portfolio
Initiated production of product components at scale at the Company's Silver
Read more →VNRXGeneral
of VolitionRx Limited, dated
VolitionRx Limited Announces First Quarter 2021 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for
Wednesday, May 12, at 8:00 a.m. U.S. Eastern Time
Secured strongest-ever balance sheet with approximately $33.1 mill
Read more →VNRXConferences/Events
VolitionRx Limited Schedules First Quarter 2021 Earnings Conference Call and Business Update
AUSTIN, Texas, May 6, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Wednesday May 12, at 8:00 a.m. Eastern time to discuss its financial and operating results for the first quarter of 2021, in addition
Read more →VNRXGeneral
VolitionRx Limited Announces Publication of Significant Nu.Q® Capture Mass Spectrometry Paper
AUSTIN, Texas, March 31, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals,
Read more →VNRXGeneral
of VolitionRx Limited Regarding Appointment of Directors, dated
VolitionRx Limited Appoints Two New Directors
AUSTIN, Texas, March 29, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers
Read more →VNRXGeneral
VolitionRx Limited Appoints Two New Directors
AUSTIN, Texas, March 29, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals,
Read more →VNRXConferences/Events
VolitionRx Limited Schedules Full Fiscal Year 2020 Earnings Conference Call and Business Update
AUSTIN, Texas, March 16, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Tuesday, March 23, at 8:00 a.m. Eastern time to discuss its financial and operating results for the full fiscal year 2020, in addi
Read more →VNRXGeneral
VolitionRx Limited Announces Pricing of $20 Million Underwritten Public Offering of Common Stock
VolitionRx Limited Announces Pricing of $20 Million Underwritten Public Offering of Common Stock
AUSTIN, Texas, February 10, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company that applies its Nucleosomics platform th
Read more →VNRXGeneral
VolitionRx Provides a Business Update and Appoints Key Officers to Drive Commercialization Efforts
VolitionRx Provides a Business Update and Appoints Key Officers to Drive Commercialization Efforts
AUSTIN, Texas, February 2, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today provided a business update and announced the appointment of a new Chief
Read more →VNRXGeneral
VolitionRx Limited Opens its New Manufacturing Facility in Belgium
AUSTIN, Texas, Jan. 25, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the opening of "Silver One", its 10,000 square foot dedicated manufacturing facility located on the same science park as its Research and Development laboratory in I
Read more →VNRXGeneral
VolitionRx Limited Awarded an Additional $4 Million in Non-Dilutive Funding
AUSTIN, Texas, Jan. 6, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it has been awarded additional non-dilutive funding totaling approximately $4 million from the Walloon Region and Namur Invest, Belgium. To date, Agencies from the Wa
Read more →VNRXGeneral
VolitionRx Limited Appoints Dr. Tom Butera DVM to Board of Directors
VolitionRx Limited Appoints Dr. Tom Butera DVM to Board of Directors
AUSTIN, Texas, December 3, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help dia
Read more →VNRXConferences/Events
VolitionRx Limited Announces Third Quarter 2020 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Friday, November 13 at 8:30 a.m. U.S. Eastern
VolitionRx Limited Announces Third Quarter 2020 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for
Friday, November 13 at 8:30 a.m. U.S. Eastern Time
Launch of first product, the Nu.Q Vet Cancer Screening Test plann
Read more →VNRXGeneral
of VolitionRx Limited issued
VolitionRx Announces Proposed Underwritten Public Offering of Common Stock
AUSTIN, Texas, May 19, 2020 PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company that applies its NucleosomicsTM platform through its subsidiaries to
Read more →VNRXGeneral
issued
Volition Files Patent for Nu.QTM COVID-19 Triage Test and Commences Proof of Concept Studies
AUSTIN, Texas, April 23, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it is actively developing a COVID-19 triage test aiming to predic
Read more →VNRXGeneral
VolitionRx Announces Filing of Registration Statements
AUSTIN, Texas, Feb. 7, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has filed registration statements on Form S-3 and Form S-8, respectively, with the Securities and Exchange Commission.
The primary purpose of filing the regi
Read more →VNRXGeneral
FORM 8-K PRESS RELEASE OF VOLITIONRX LIMITED, DATED NOVEMBER 12, 2019. Form 8-K Press Release of VolitionRx Limited, dated
VolitionRx Limited Announces Third Quarter 2019 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for
Wednesday, November 13 at 8:30 a.m. U.S. Eastern Time
AUSTIN, Texas, November 12, 2019 /PRNewswire/ -- VolitionRx Li
Read more →VNRXGeneral
Volition Appoints Dr. Phillip Barnes to Board of Directors
Volition Appoints Dr. Phillip Barnes to Board of Directors
AUSTIN, Texas, October 9, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the appointment of Dr. Phillip Barnes to the Company's Board of Directors as a Non-Executive Director,
Read more →VNRXConferences/Events
VolitionRx Limited Announces First Quarter 2019 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Thursday, May 9 at 8:30 a.m. U.S. Eastern Tim
VolitionRx Limited Announces First Quarter 2019 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for
Thursday, May 9 at 8:30 a.m. U.S. Eastern Time
AUSTIN, Texas, May 8, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE A
Read more →VNRXGeneral
VolitionRx Limited Announces Third Quarter 2018 Financial Results and Business Update
VolitionRx Limited Announces Third Quarter 2018 Financial Results and Business Update
ISNES, Belgium, November 7, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the quarter ended September 30
Read more →VNRXConferences/Events
VolitionRx Limited Schedules Third Quarter 2018 Earnings Conference Call and Business Update
Conference call to take place Thursday, November 8, 2018 at 8:30 am Eastern time
ISNES, Belgium, Oct. 31, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced it will host a conference call on Thursday, November 8 at 8:30 a.m. Eastern time to discuss its
Read more →VNRXGeneral
VolitionRx Limited to Expand its Nu.Q(TM) Trials to Veterinary Diagnostics
ISNES, Belgium, Oct. 4, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced very encouraging preliminary results from a proof of concept study using its Nu.Q™ diagnostic test in veterinary medicine at the 10th anniversary meeting of the Belg
Read more →VNRXGeneral
VolitionRx Announces $9 Million Private Placement
VolitionRx Announces $9 Million Private Placement
ISNES, Belgium, August 8, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has entered into a definitive agreement with an existing accredited investor related to a private placem
Read more →VNRXGeneral
Volition Secures Additional $700,000 Non-Dilutive Funding from the Walloon Region
ISNES, Belgium, July 2, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has been awarded additional non-dilutive funding of approximately $700,000 from the Walloon Regional Government. Including this latest amount, Volition has r
Read more →VNRXGeneral
VolitionRx Limited Announces First Quarter 2018 Financial Results and Business Update
VolitionRx Limited Announces First Quarter 2018 Financial Results and Business Update
ISNES, Belgium, May 10, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition") today announced financial results and a business update for the first quarter ended March 31,
Read more →VNRXConferences/Events
VolitionRX Limited Announces Full Fiscal Year 2017 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Friday, March 2 at 8:30 a.m. Eastern Time
VolitionRX Limited Announces Full Fiscal Year 2017 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for
Friday, March 2 at 8:30 a.m. Eastern Time
ISNES, Belgium, March 1, 2018 /PRNewswire/ -- VolitionRX Limited (NYSE
Read more →VNRXPhases
VolitionRx Limited Announces Interim Results from 680-Subject Clinical Trial in Colorectal Cancer
Study demonstrates high detection rates of Stage I cancer and pre-cancerous adenomas in colorectal cancer screening trial for Nu.QTM blood test
Conference call to discuss interim results scheduled for Tuesday, February 27 at 8:30 a.m. Eastern Time
ISNES, Belgium, Feb. 26, 2018
Read more →VNRXGeneral
of VolitionRx Limited VolitionRx Limited Announces Third Quarter 2017 Financial Results and Business Update
VolitionRx Limited Announces Third Quarter 2017 Financial Results and Business Update
ISNES, Belgium, November 9, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced financial results and a business update for the third quarter ended September 30, 2017.
Read more →VNRXConferences/Events
VolitionRx Limited Schedules Third Quarter 2017 Earnings Conference Call and Business Update
Conference call to take place Friday, November 10, 2017 at 8:30 am Eastern time
ISNES, Belgium, Nov. 2, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced it will host a conference call on Friday, November 10 at 8:30 a.m. Eastern time to discuss its fi
Read more →VNRXGeneral
VolitionRx Limited Awarded $1.5 Million in Non-Dilutive Funding
ISNES, Belgium, Sept. 21, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has been awarded a loan and a non-repayable grant totaling $1.5 million from SOFINEX and the Walloon Region, Belgium. This is in addition to the $947,000 i
Read more →VNRXGeneral
Press Release
VolitionRx Limited Announces Second Quarter 2017 Financial Results and Business Update
ISNES, Belgium, August 9, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the quarter ended June 30, 2017
Read more →VNRXConferences/Events
VolitionRx Limited Schedules Second Quarter 2017 Earnings Conference Call and Business Update
Conference call to take place Thursday, August 10, 2017 at 8:30 am Eastern time
ISNES, Belgium, Aug. 3, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) today announced it will host a conference call on Thursday, August 10, 2017 at 8:30 am Eastern time to discuss it
Read more →VNRXConferences/Events
VolitionRx Limited to host a conference call regarding a 13,500 Subject Colorectal Cancer Screening Trial with the Early Detection Research Network of the U.S. National Cancer Institute
AUSTIN, Texas, July 19, 2017 /PRNewswire/ -- VolitionRx Limited (Volition; NYSE MKT: VNRX), announced it will host a conference call tomorrow, July 20 at 8:30 AM U.S. Eastern Time to discuss its participation in a large multi-center clinical study with the Great Lakes New England
Read more →VNRXConferences/Events
VolitionRx Limited to Present at Multiple Investor Conferences in June
NAMUR, Belgium, May 26, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) today announced it is scheduled to present at multiple investor conferences in June.
Dr. Scott Powell, Executive Vice President of Volition, will provide an update on Volition's business, clinical,
Read more →VNRXGeneral
VolitionRx Limited Announces First Quarter 2017 Financial Results and Business Update
VolitionRx Limited Announces First Quarter 2017 Financial Results and Business Update
NAMUR, Belgium, May 11, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) ( Volition ) today announced financial results for the quarter ended March 31, 2017 and provided a business upda
Read more →VNRXGeneral
Volition opens a new Research and Development facility in Belgium with a state of the art, purpose-built laboratory
NAMUR, Belgium, April 21, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) opened its new research and development facility this week. A video showcasing the new facility and opening event is available to view at http://volitionrx.com/news/video-gallery
The new building
Read more →VNRXGeneral
VolitionRx Appoints David Vanston as Chief Financial Officer
VolitionRx Appoints David Vanston as Chief Financial Officer
NAMUR, Belgium, April 11, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), is delighted to announce that David Vanston (FCCA, MBA) joined Volition as its new Chief Financial Officer, effective 10th April 2017.
Read more →VNRXGeneral
Volition America, Inc. Retains Strategic Expert in Securing Non-Dilutive Funding Opportunities in the United States
NAMUR, Belgium, March 28, 2017 /PRNewswire/ -- Volition America, Inc., a wholly-owned U.S. subsidiary of VolitionRx Limited (NYSE MKT: VNRX), today announced the engagement of Deborah Vollmer Dahlke, DrPH, CEO and President of DVD Associates, LLC, as a strategic consultant. Dr. V
Read more →VNRXGeneral
VolitionRx Limited Announces the Formation of Volition America, Inc.
NAMUR, Belgium, March 20, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) today announced the creation of a wholly-owned U.S. subsidiary, Volition America, Inc., which will be based in Austin, Texas. Dr. Jason Terrell, Chief Medical Officer of Volition, has been appointe
Read more →VNRXGeneral
VolitionRx Limited Celebrates CE Mark Announcement By Ringing Closing Bell at the New York Stock Exchange
NAMUR, Belgium, March 14, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) celebrated the company's recent announcement of a CE mark for its Nu.QTM Colorectal Cancer Screening Triage Test by ringing the closing bell at the New York Stock Exchange (NYSE) on Monday, March 1
Read more →VNRXGeneral
VolitionRx Limited to Ring the New York Stock Exchange Closing Bell on Monday, March 13th at 4 pm Eastern Daylight Time
NAMUR, Belgium, March 13, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) announced today that members of its senior management team and Board of Directors, including Chief Executive Officer, Cameron Reynolds, will ring the closing bell at the New York Stock Exchange (NY
Read more →VNRXGeneral
VolitionRx Limited Announces Third Quarter 2016 Financial Results and Business Update
VolitionRx Limited Announces Third Quarter 2016 Financial Results and Business Update
NAMUR, Belgium, Nov. 10, 2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) today announced financial results for the third quarter ended September 30, 2016 and provided a business update
Read more →VNRXGeneral
VolitionRx Limited Announces Acquisition of New Belgian Facility and Appointment of COO to Belgian Volition
VolitionRx Limited Announces Acquisition of New Belgian Facility and Appointment of COO to Belgian Volition
NAMUR, Belgium, Oct. 26, 2016 /PRNewswire/ --VolitionRx Limited (NYSE MKT: VNRX), today announced its acquisition of a new research and development facility located in the
Read more →VNRXGeneral
092916 VolitionRx Limited Announces Proposed Public Offering of Common Stock
VolitionRx Limited Announces Proposed Public Offering of Common Stock
NAMUR, Belgium, Sept. 29, 2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing diagnostic tests for cancer, today announced that it intends to offer and sell
Read more →VNRXGeneral
VolitionRx Announces Second Quarter 2016 Financial Results and Business Update
VolitionRx Announces Second Quarter 2016 Financial Results and Business Update
NAMUR, Belgium, Aug. 11, 2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing diagnostic tests for cancer and other conditions, today announced finan
Read more →VNRXGeneral
VolitionRx Appoints Dr. Edward Futcher to Board of Directors Appointment to help guide Company s strategic direction ahead of EU and U.S. market entry of NuQ blood tests
VolitionRx Appoints Dr. Edward Futcher to Board of Directors
Appointment to help guide Company s strategic direction ahead of EU and U.S. market entry of NuQ blood tests
NAMUR, Belgium, June 24, 2016 - VolitionRx Limited (NYSE MKT: VNRX), today announced the appointment of Dr.
Read more →VNRXGeneral
VolitionRx Announces First Quarter 2016 Financial Results and Business Update Namur, Belgium
VolitionRx Announces First Quarter 2016 Financial Results and Business Update
Namur, Belgium, May 13, 2016 - VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, to
Read more →VNRXGeneral
VolitionRx Announces Proposed Public Offering of Common Stock Namur, Belgium
VolitionRx Announces Proposed Public Offering of Common Stock
Namur, Belgium, March 17, 2016 VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, announced today th
Read more →VNRXGeneral
VolitionRx Announces Full Year 2015 Financial Results and Business Update Namur, Belgium
VolitionRx Announces Full Year 2015 Financial Results and Business Update
Namur, Belgium, March 11, 2016 - VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, toda
Read more →VNRXGeneral
VolitionRx Announces Dr. Jason Terrell s Transition to Full-Time Status as Chief Medical Officer and Head of U.S. Operations
VolitionRx Announces Dr. Jason Terrell s Transition to Full-Time Status
as Chief Medical Officer and Head of U.S. Operations
NAMUR, Belgium, January 5, 2016 - VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a b
Read more →VNRXConferences/Events
VolitionRx to Present at Two Conferences in November CEO to speak at Canaccord Genuity Medical Technology & Diagnostics Forum and Biotech Capital Conference
VolitionRx to Present at Two Conferences in November
CEO to speak at Canaccord Genuity Medical Technology & Diagnostics Forum and Biotech Capital Conference
NAMUR, Belgium November 12, 2015 VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood
Read more →VNRXGeneral
C O R P O R A T E P A R T I C I P A N T S Scott Powell, Director of Investor Relations Cameron Reynolds, President and Chief Executive Officer C O N F E R E N C E C A L L P A R T I C I P A N T S Bruce Jackson, Lake Stree
C O R P O R A T E P A R T I C I P A N T S
Scott Powell, Director of Investor Relations
Cameron Reynolds, President and Chief Executive Officer
C O N F E R E N C E C A L L P A R T I C I P A N T S
Bruce Jackson, Lake Street Capital Markets
Brian Marckx, Zacks Investment Resear
Read more →VNRXGeneral
VolitionRx Announces Appointment of David Kratochvil as Chief Financial Officer
VolitionRx Announces Appointment of David Kratochvil as Chief Financial Officer
NAMUR, Belgium, August 17, 2015 - VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other condition
Read more →VNRXConferences/Events
Transcript of Conference Call C O R P O R A T E P A R T I C I P A N T S Scott Powell, Director of Investor Relations Cameron Reynolds, President and Chief Executive Officer C O N F E R E N C E C A L L P A R T I C I P A N
C O R P O R A T E P A R T I C I P A N T S
Scott Powell, Director of Investor Relations
Cameron Reynolds, President and Chief Executive Officer
C O N F E R E N C E C A L L P A R T I C I P A N T S
Bruce Jackson, Lake Street Capital Markets
Brian Marckx, Zacks Investment Resear
Read more →VNRXConferences/Events
Updated Conference Call Transcript VolitionRx Limited First Quarter 2015 Financial Earnings and Business Update Conference Call Transcript
VolitionRx Limited First Quarter 2015 Financial Earnings
and Business Update Conference Call Transcript
CORPORATE PARTICIPANTS
Scott Powell, Director of Investor Relations
Cameron Reynolds, President and Chief Executive Officer
CONFERENCE CALL PARTICIPANTS
Brian Marckx, Zac
Read more →VNRXGeneral
VolitionRx Acquires Direct Ownership of Nucleosomics® Technology Patent
NAMUR, Belgium, Feb. 24, 2015 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that it has just acquired the unencumbered assignm
Read more →VNRXGeneral
VolitionRx Limited Prices Public Offering of Common Stock 2,475,000 Shares Priced at $3.75 Per Share Shares Expected to Begin Trading on NYSE MKT on
VolitionRx Limited Prices Public Offering of Common Stock
2,475,000 Shares Priced at $3.75 Per Share
Shares Expected to Begin Trading on NYSE MKT on February 6, 2015
Namur, Belgium, Feb. 6, 2015 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focus
Read more →VNRXPhases
VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014
NAMUR, Belgium, Nov. 24, 2014 /PRNewswire/ -- VolitionRx Limited (OTCQB: VNRX), a life sciences company focused on developing diagnostic tests for cancer and other conditions, today announced that data from its pilot lung cancer study will be presented at the Science for Business
Read more →VNRXConferences/Events
VolitionRx to Present at the SeeThruEquity Conference
NAMUR, Belgium, Nov. 5, 2014 /PRNewswire/ -- VolitionRx Limited (OTCQB: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that its Chief Executive Officer, Cameron Reynolds, is
Read more →VNRXGeneral
VolitionRx Initiates Sponsorship of Two-time Cancer Survivor to Drive Awareness for the Importance of Early Cancer Detection
NAMUR, Belgium, Oct. 31, 2014 /PRNewswire/ -- VolitionRx Limited (OTCQB: VNRX), a life sciences company focused on developing blood-based diagnostic tests, today announced that it has initiated sponsorship of Sean Swarner, the first cancer survivor to summit Mt. Everest, to raise
Read more →VNRXGeneral
VolitionRx Announces Prostate Cancer Collaboration with the University of Texas MD Anderson Cancer Center
NAMUR, Belgium, Oct. 2, 2014 /PRNewswire/ --VolitionRx Limited (OTCQB: VNRX), a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, today announced a study collaboration with The University of Texas MD Anderson Cancer Center's D
Read more →VNRXConferences/Events
VolitionRx to Present at the Aegis Capital Corp. 2014 Healthcare & Technology Conference
NAMUR, Belgium, Sept. 5, 2014 /PRNewswire/ -- VolitionRx Limited (OTCQB: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types, today announced that its Chief Executive Officer, Cameron Reynolds, is scheduled to presen
Read more →VNRXGeneral
VOLITIONRX COMPLETES $3 MILLION PRIVATE PLACEMENT NAMUR, BELGIUM--(Marketwired
VOLITIONRX COMPLETES $3 MILLION PRIVATE PLACEMENT
NAMUR, BELGIUM--(Marketwired February 28, 2014) - VolitionRx Limited (OTCQB: VNRX), a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, today announced the completion of a pri
Read more →VNRXGeneral
VolitionRx Finds Simple Blood Test Detects 85% of Colorectal Cancers and Over 50% of Polyps
NAMUR, Belgium, Dec. 2, 2013 /PRNewswire/ -- VolitionRx Limited (VNRX:OB), a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, today releases new data showing that when combining two of its proprietary NuQ® assays into one tes
Read more →VNRXConferences/Events
VolitionRx to Present at the 6th Annual LD Micro Conference
NAMUR, Belgium, Nov. 29, 2013 /PRNewswire/ -- VolitionRx Limited (VNRX:OB), a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, today announces it will be presenting at the Sixth Annual LD Micro Conference.
Cameron Reynolds,
Read more →VNRXPhases
VolitionRx Expands Sample Size to 11,000 in Pivotal Colorectal Cancer Trial with Hvidovre Hospital, Denmark
NAMUR, Belgium, Nov. 14, 2013 /PRNewswire/ -- VolitionRx Limited (VNRX:OB), a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, today announced an increase of 55% (from 6,000 to 11,000) in the number of prospective blood sampl
Read more →VNRXConferences/Events
First VolitionRx Study Data Presented at CNAPS, Baltimore
BALTIMORE, Nov. 7, 2013 /PRNewswire/ -- VolitionRx Limited (OTC: VNRX), a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, today announces the publication of preliminary data from an ongoing independent trial of one of its Nu
Read more →VNRXGeneral
VolitionRx and Active Motif enter into Distribution Agreement for Volition
NAMUR, Belgium, Sept. 26, 2013 /PRNewswire/ -- VolitionRx Limited (OTC: VNRX), a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, today entered into an agreement with Active Motif, a leading provider of kits and reagents to e
Read more →VNRXGeneral
VolitionRx-led Consortium Awarded euro 780 000 ($1M approx.) Eurostars Grant
NAMUR, Belgium, Sept. 3, 2013 /PRNewswire/ -- VolitionRx Limited (OTC: VNRX), a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, is lead partner of a consortium in a project valued at €779,493 (approx. US$1M) under the EUREKA
Read more →VNRXGeneral
VolitionRx to use Innova Biosciences
NAMUR, Belgium, July 22, 2013 /PRNewswire/ -- VolitionRx Limited (OTC: VNRX), a life sciences company focused on the development of blood-based diagnostic tests, has signed a non-exclusive in-licensing agreement with Innova Biosciences, a specialist provider of bioconjugation sys
Read more →VNRXGeneral
Racepoint Group Appointed by VolitionRx to Raise Awareness of its new Early-Stage Cancer Diagnostic
NAMUR, Belgium, May 1, 2013 /PRNewswire/ -- VolitionRx Limited (OTC: VNRX), a life sciences company that is developing blood-based diagnostic tests for different types of cancer, has retained Racepoint Group as its public relations agency of record. The company's tests are based
Read more →VNRXGeneral
VolitionRx Files Two Patent Applications
NAMUR, Belgium, April 4, 2013 /PRNewswire/ -- VolitionRx Limited (OTC: VNRX), a life sciences company focused on developing blood-based diagnostic tests, announces that it has filed two new patent applications. The first patent application is an extension to the Nucleosomics® tec
Read more →VNRXGeneral
VolitionRx Hires Head of US Operations, Jason Terrell MD
SINGAPORE, March 26, 2013 /PRNewswire/ -- VolitionRx Limited (OTC: VNRX), a life sciences company focused on developing blood-based diagnostic tests, announces that it has hired Jason Terrell MD as Head of US Operations. Dr Terrell will initially be responsible for facilitating V
Read more →VNRXGeneral
VolitionRx Announces Collaboration with Wales Cancer Bank
NAMUR, Belgium, Jan. 9, 2013 /PRNewswire/ -- VolitionRx Limited (OTC: VNRX), a life sciences company focused on developing blood-based diagnostic tests, announces that it will commence a large internal clinical study for its Nucleosomics® diagnostic products this month. This tria
Read more →VNRXGeneral
Volition Launches NuQ® Epigenetic Immunoassays for Research Use
SINGAPORE, Dec. 17, 2012 /PRNewswire/ -- VolitionRx Limited (OTC: VNRX), a life sciences company focused on developing blood-based diagnostic tests, announces the launch of NuQ®, its range of research use only epigenetic immunoassays, to be available for sale at www.nucleosomics.
Read more →VNRXGeneral
VolitionRx
SINGAPORE, Nov. 5, 2012 /PRNewswire/ -- VolitionRx Limited (OTC: VNRX), a life sciences company focused on developing blood-based diagnostic tests, today announced preliminary findings from its ongoing internal clinical trials of the NuQ® diagnostic platform. VolitionRx has analy
Read more →VNRXPhases
VolitionRX to Begin Prospective Clinical Trial in Colon Cancer
SINGAPORE, Aug. 21, 2012 /PRNewswire/ -- VolitionRX Limited, a life sciences company focused on developing blood-based diagnostic tests, announces that its subsidiary Belgian Volition has signed an agreement with the Biobank of CHU UCL Mont-Godinne, an academic hospital in Yvoir,
Read more →VNRXGeneral
VolitionRX Issues CEO Letter to Shareholders
SINGAPORE, July 16, 2012 /PRNewswire/ -- VolitionRX Limited (VNRX.OB), a life sciences company focused on developing blood-based diagnostic tests, issues the following letter to shareholders from CEO Cameron Reynolds:
To our valued shareholders,
It has been a very busy nine mon
Read more →VNRXGeneral
VolitionRX Signs Collaboration Agreement With Stefan Holdenrieder of Rheinische Friedrich-Wilhelms-Universitat Bonn Germany
SINGAPORE, July 9, 2012 /PRNewswire/ -- VolitionRX Limited (OTC:VNRX.OB), a life sciences company focused on developing blood-based diagnostic tests, is pleased to announce that it has entered into a collaboration agreement with Rheinische Friedrich-Wilhelms-Universitat Bonn ("Bo
Read more →VNRXPhases
VolitionRX Raises Over $1 Million To Begin Clinical Trials of Blood Based Diagnostic Tests
SINGAPORE, May 14, 2012 /PRNewswire/ -- VolitionRX Limited (VNRX.OB), a life sciences company focused on developing blood-based diagnostic tests, is pleased to announce the closure of a private placement of 582,510 shares at $1.75 per share (a total of US$$1,019,375.00 raised). T
Read more →VNRXGeneral
Pioneering New Science Nucleosomics Advances Blood Based Diagnostics for Cancer
LONDON, March 27, 2012 /PRNewswire/ -- The ability to diagnose disease early has long been a goal in the medical arena. VolitionRX (VNRX.OB), a life sciences company, is pioneering scientific research into simple, cost-effective tools capable of diagnosing the early presence of d
Read more →VNRXGeneral
Volition Signs Collaboration Agreement With Abcodia
SINGAPORE, Feb. 17, 2012 /PRNewswire/ -- VolitionRX Limited (VNRX.OB), a life sciences company focused on developing blood-based diagnostic tests, announces a collaboration agreement with Abcodia, a specialist company spun out from University College London (UCL), under which Vol
Read more →VNRXGeneral
VolitionRX Limited Intellectual Property Update: New Patent Filed
SINGAPORE, Dec. 22, 2011 /PRNewswire/ -- VolitionRX Limited (VNRX.OB), a life sciences company focused on developing blood-based diagnostic tests, is pleased to announce that it has filed a further patent application building on its Nucleosomics technology platform.
VolitionRX h
Read more →VNRXGeneral
VolitionRX Limited Issues 525,000 Shares to ValiRx; Final Requirement of Share Purchase Agreement
SINGAPORE, Dec. 9, 2011 /PRNewswire/ -- VolitionRX Limited (VNRX.OB), a life sciences company focused on developing blood-based diagnostic tests, is pleased to announce that it will issue US$1,110,000 worth of shares of its common stock to AIM-listed company, ValiRx PLC. The shar
Read more →VNRXGeneral
VolitionRX Subsidiary Enters Into its First Revenue-Generating Agreement to Profile Blood-Based Epigenetic Signatures
SINGAPORE, Nov. 15, 2011 /PRNewswire/ -- VolitionRX Limited ("Volition") (VNRX.OB), a life sciences company focused on developing blood-based diagnostic tests, is pleased to announce that its wholly owned subsidiary, HyperGenomics Pte Limited ("HyperGenomics"), has signed a contr
Read more →VNRXGeneral
Volition Names Clinical Evaluation Committee
SINGAPORE, Nov. 9, 2011 /PRNewswire/ -- VolitionRX Limited (VNRX.OB), a life sciences company focused on developing blood-based diagnostic tests, is pleased to announce that it has named a Clinical Evaluation Management Committee. The committee will act as a semi-independent advi
Read more →VNRXGeneral
VolitionRX Limited Issues Update Letter to Shareholders
SINGAPORE, Oct. 31 2011 /PRNewswire/ -- VolitionRX Limited (VNRX.OB) ("Volition" or the "Company"), a life sciences company focused on developing blood-based diagnostic tests, publishes the following letter to its shareholders from Cameron Reynolds, CEO:
Given the speed at which
Read more →VNRXGeneral
Volition Ticker Symbol Changed to VNRX.OB; Name Change to VolitionRX Limited Completed
SINGAPORE, Oct. 11 2011 /PRNewswire/ -- Volition, a life sciences company focused on developing blood-based diagnostic tests, has been advised by FINRA that the regulator has received the necessary documentation to announce a name change to VolitionRX Limited, and a change of sym
Read more →VNRXGeneral
Volition Announces Closure of Share Exchange Agreement
SINGAPORE, Oct. 7, 2011 /PRNewswire/ -- Singapore Volition Pte Limited ("Volition"), a life sciences company focused on developing blood-based diagnostic tests, today announces the closure of the Share Exchange Agreement with Standard Capital Corporation, a Delaware corporation c
Read more →